-
1
-
-
84872967522
-
Cancer statistics, 2013
-
Siegel, R.; Naishadham, D.; Jemal, A. Cancer statistics, 2013. CA Cancer J. Clin. 2013, 63, 11-30.
-
(2013)
CA Cancer J. Clin
, vol.63
, pp. 11-30
-
-
Siegel, R.1
Naishadham, D.2
Jemal, A.3
-
2
-
-
76049128595
-
Estimates of cancer incidence and mortality in Europe in 2008
-
Ferlay, J.; Parkin, D.M.; Steliarova-Foucher, E. Estimates of cancer incidence and mortality in Europe in 2008. Eur. J. Cancer 2010, 46, 765-781.
-
Eur. J. Cancer
, vol.2010
, Issue.46
, pp. 765-781
-
-
Ferlay, J.1
Parkin, D.M.2
Steliarova-Foucher, E.3
-
3
-
-
77956511576
-
Prostate cancer screening: Current status and future perspectives
-
Strope, S.A.; Andriole, G.L. Prostate cancer screening: Current status and future perspectives. Nat. Rev. Urol. 2010, 7, 487-493.
-
(2010)
Nat. Rev. Urol
, vol.7
, pp. 487-493
-
-
Strope, S.A.1
Andriole, G.L.2
-
4
-
-
0028365543
-
Prostate-specific antigen and digital rectal examination in screening for prostate cancer: A community-based study
-
Bretton, P.R. Prostate-specific antigen and digital rectal examination in screening for prostate cancer: A community-based study. South Med. J. 1994, 87, 720-723.
-
(1994)
South Med. J
, vol.87
, pp. 720-723
-
-
Bretton, P.R.1
-
5
-
-
0028256194
-
Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: Results of a multicenter clinical trial of 6630 men
-
Catalona, W.J.; Richie, J.P.; Ahmann, F.R.; Hudson, M.A.; Scardino, P.T.; Flanigan, R.C.; deKernion, J.B.; Ratliff, T.L.; Kavoussi, L.R.; Dalkin, B.L. et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: Results of a multicenter clinical trial of 6630 men. J. Urol. 1994, 151, 1283-1290.
-
(1994)
J. Urol
, vol.151
, pp. 1283-1290
-
-
Catalona, W.J.1
Richie, J.P.2
Ahmann, F.R.3
Hudson, M.A.4
Scardino, P.T.5
Flanigan, R.C.6
Dekernion, J.B.7
Ratliff, T.L.8
Kavoussi, L.R.9
Dalkin, B.L.10
-
6
-
-
0025849053
-
Measurement of prostate-specific antigen in serum as a screening test for prostate cancer
-
Catalona, W.J.; Smith, D.S.; Ratliff, T.L.; Dodds, K.M.; Coplen, D.E.; Yuan, J.J.; Petros, J.A.; Andriole, G.L. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N. Engl. J. Med. 1991, 324, 1156-1161.
-
(1991)
N. Engl. J. Med
, vol.324
, pp. 1156-1161
-
-
Catalona, W.J.1
Smith, D.S.2
Ratliff, T.L.3
Dodds, K.M.4
Coplen, D.E.5
Yuan, J.J.6
Petros, J.A.7
Andriole, G.L.8
-
7
-
-
77953435844
-
New tests for prostate cancer may be nearing the clinic
-
Tuma, R.S. New tests for prostate cancer may be nearing the clinic. J. Natl. Cancer Inst. 2010, 102, 752-754.
-
(2010)
J. Natl. Cancer Inst
, vol.102
, pp. 752-754
-
-
Tuma, R.S.1
-
8
-
-
21444447966
-
Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/mL or lower
-
Thompson, I.M.; Ankerst, D.P.; Chi, C.; Lucia, M.S.; Goodman, P.J.; Crowley, J.J.; Parnes, H.L.; Coltman, C.A., Jr. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/mL or lower. JAMA 2005, 294, 66-70.
-
(2005)
JAMA
, vol.294
, pp. 66-70
-
-
Thompson, I.M.1
Ankerst, D.P.2
Chi, C.3
Lucia, M.S.4
Goodman, P.J.5
Crowley, J.J.6
Parnes, H.L.7
Coltman Jr., C.A.8
-
9
-
-
2442715038
-
Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter
-
Thompson, I.M.; Pauler, D.K.; Goodman, P.J.; Tangen, C.M.; Lucia, M.S.; Parnes, H.L.; Minasian, L.M.; Ford, L.G.; Lippman, S.M.; Crawford, E.D., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N. Engl. J. Med. 2004, 350, 2239-2246.
-
(2004)
N. Engl. J. Med
, vol.350
, pp. 2239-2246
-
-
Thompson, I.M.1
Pauler, D.K.2
Goodman, P.J.3
Tangen, C.M.4
Lucia, M.S.5
Parnes, H.L.6
Minasian, L.M.7
Ford, L.G.8
Lippman, S.M.9
Crawford, E.D.10
-
10
-
-
0343593693
-
Prostate cancer detection at low prostate specific antigen
-
Schroder, F.H.; van der Cruijsen-Koeter, I.; de Koning, H.J.; Vis, A.N.; Hoedemaeker, R.F.; Kranse, R. Prostate cancer detection at low prostate specific antigen. J. Urol. 2000, 163, 806-812.
-
(2000)
J. Urol
, vol.163
, pp. 806-812
-
-
Schroder, F.H.1
van der Cruijsen-Koeter, I.2
de Koning, H.J.3
Vis, A.N.4
Hoedemaeker, R.F.5
Kranse, R.6
-
11
-
-
39749142228
-
The search for new cardiovascular biomarkers
-
Gerszten, R.E.; Wang, T.J. The search for new cardiovascular biomarkers. Nature 2008, 451, 949-952.
-
(2008)
Nature
, vol.451
, pp. 949-952
-
-
Gerszten, R.E.1
Wang, T.J.2
-
12
-
-
79951545823
-
Evolution of Clinical Proteomics and its Role in Medicine
-
Boja, E.; Hiltke, T.; Rivers, R.; Kinsinger, C.; Rahbar, A.; Mesri, M.; Rodriguez, H. Evolution of Clinical Proteomics and its Role in Medicine. J. Proteome Res. 2010, 10, 66-84.
-
(2010)
J. Proteome Res
, vol.10
, pp. 66-84
-
-
Boja, E.1
Hiltke, T.2
Rivers, R.3
Kinsinger, C.4
Rahbar, A.5
Mesri, M.6
Rodriguez, H.7
-
13
-
-
14844311934
-
Candidate-based proteomics in the search for biomarkers of cardiovascular disease
-
Anderson, L. Candidate-based proteomics in the search for biomarkers of cardiovascular disease. J. Physiol. 2005, 563, 23-60.
-
(2005)
J. Physiol
, vol.563
, pp. 23-60
-
-
Anderson, L.1
-
14
-
-
67651249913
-
Clinical collection and protein properties of expressed prostatic secretions as a source for biomarkers of prostatic disease
-
Drake, R.R.; White, K.Y.; Fuller, T.W.; Igwe, E.; Clements, M.A.; Nyalwidhe, J.O.; Given, R.W.; Lance, R.S.; Semmes, O.J. Clinical collection and protein properties of expressed prostatic secretions as a source for biomarkers of prostatic disease. J. Proteomics 2009, 72, 907-917.
-
(2009)
J. Proteomics
, vol.72
, pp. 907-917
-
-
Drake, R.R.1
White, K.Y.2
Fuller, T.W.3
Igwe, E.4
Clements, M.A.5
Nyalwidhe, J.O.6
Given, R.W.7
Lance, R.S.8
Semmes, O.J.9
-
15
-
-
79953243174
-
Exosomes as biomarker treasure chests for prostate cancer
-
Duijvesz, D.; Luider, T.; Bangma, C.H.; Jenster, G. Exosomes as biomarker treasure chests for prostate cancer. Eur. Urol. 2011, 59, 823-831.
-
(2011)
Eur. Urol
, vol.59
, pp. 823-831
-
-
Duijvesz, D.1
Luider, T.2
Bangma, C.H.3
Jenster, G.4
-
16
-
-
0000489689
-
Exfoliative cytology of urinary sediments; a review of 2829 cases
-
Foot, N.C.; Papanicolaou, G.N.; Holmquist, N.D.; Seybolt, J.F. Exfoliative cytology of urinary sediments; a review of 2829 cases. Cancer 1958, 11, 127-137.
-
(1958)
Cancer
, vol.11
, pp. 127-137
-
-
Foot, N.C.1
Papanicolaou, G.N.2
Holmquist, N.D.3
Seybolt, J.F.4
-
17
-
-
0034006623
-
Prostatic adenocarcinoma diagnosed by urinary cytology
-
Krishnan, B.; Truong, L.D. Prostatic adenocarcinoma diagnosed by urinary cytology. Am. J. Clin. Pathol. 2000, 113, 29-34.
-
(2000)
Am. J. Clin. Pathol
, vol.113
, pp. 29-34
-
-
Krishnan, B.1
Truong, L.D.2
-
18
-
-
33747030845
-
Protein biomarker discovery and validation: The long and uncertain path to clinical utility
-
Rifai, N.; Gillette, M.A.; Carr, S.A. Protein biomarker discovery and validation: The long and uncertain path to clinical utility. Nat. Biotechnol. 2006, 24, 971-983.
-
(2006)
Nat. Biotechnol
, vol.24
, pp. 971-983
-
-
Rifai, N.1
Gillette, M.A.2
Carr, S.A.3
-
19
-
-
83055179651
-
Innovative biomarkers for prostate cancer early diagnosis and progression
-
You, J.; Cozzi, P.; Walsh, B.; Willcox, M.; Kearsley, J.; Russell, P.; Li, Y. Innovative biomarkers for prostate cancer early diagnosis and progression. Crit. Rev. Oncol. Hematol. 2010, 73, 10-22.
-
(2010)
Crit. Rev. Oncol. Hematol
, vol.73
, pp. 10-22
-
-
You, J.1
Cozzi, P.2
Walsh, B.3
Willcox, M.4
Kearsley, J.5
Russell, P.6
Li, Y.7
-
20
-
-
33845529343
-
Detection of alpha-methylacyl-coenzyme-A racemase transcripts in blood and urine samples of prostate cancer patients
-
Zehentner, B.K.; Secrist, H.; Zhang, X.; Hayes, D.C.; Ostenson, R.; Goodman, G.; Xu, J.; Kiviat, M.; Kiviat, N.; Persing, D.H., et al. Detection of alpha-methylacyl-coenzyme-A racemase transcripts in blood and urine samples of prostate cancer patients. Mol. Diagn Ther. 2006, 10, 397-403.
-
(2006)
Mol. Diagn Ther
, vol.10
, pp. 397-403
-
-
Zehentner, B.K.1
Secrist, H.2
Zhang, X.3
Hayes, D.C.4
Ostenson, R.5
Goodman, G.6
Xu, J.7
Kiviat, M.8
Kiviat, N.9
Persing, D.H.10
-
21
-
-
2942612648
-
Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer
-
Sreekumar, A.; Laxman, B.; Rhodes, D.R.; Bhagavathula, S.; Harwood, J.; Giacherio, D.; Ghosh, D.; Sanda, M.G.; Rubin, M.A.; Chinnaiyan, A.M. Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer. J. Natl. Cancer Inst. 2004, 96, 834-843.
-
(2004)
J. Natl. Cancer Inst
, vol.9
, pp. 834-843
-
-
Sreekumar, A.1
Laxman, B.2
Rhodes, D.R.3
Bhagavathula, S.4
Harwood, J.5
Giacherio, D.6
Ghosh, D.7
Sanda, M.G.8
Rubin, M.A.9
Chinnaiyan, A.M.10
-
22
-
-
4444226979
-
Identification and proteomic profiling of exosomes in human urine
-
Pisitkun, T.; Shen, R.F.; Knepper, M.A. Identification and proteomic profiling of exosomes in human urine. Proc. Natl. Acad. Sci. USA 2004, 101, 13368-13373.
-
(2004)
Proc. Natl. Acad. Sci. USA
, vol.101
, pp. 13368-13373
-
-
Pisitkun, T.1
Shen, R.F.2
Knepper, M.A.3
-
23
-
-
33846575717
-
Differential radioactive quantification of protein abundance ratios between benign and malignant prostate tissues: Cancer association of annexin A3
-
Wozny, W.; Schroer, K.; Schwall, G.P.; Poznanovic, S.; Stegmann, W.; Dietz, K.; Rogatsch, H.; Schaefer, G.; Huebl, H.; Klocker, H., et al. Differential radioactive quantification of protein abundance ratios between benign and malignant prostate tissues: Cancer association of annexin A3. Proteomics 2007, 7, 313-322.
-
(2007)
Proteomics
, vol.7
, pp. 313-322
-
-
Wozny, W.1
Schroer, K.2
Schwall, G.P.3
Poznanovic, S.4
Stegmann, W.5
Dietz, K.6
Rogatsch, H.7
Schaefer, G.8
Huebl, H.9
Klocker, H.10
-
25
-
-
84882449183
-
APC gene hypermethylation and prostate cancer: A systematic review and meta-analysis
-
doi:10.1038/ejhg.2012.281
-
Chen, Y.; Li, J.; Yu, X.; Li, S.; Zhang, X.; Mo, Z.; Hu, Y. APC gene hypermethylation and prostate cancer: A systematic review and meta-analysis. Eur. J. Hum. Genet. 2013, doi:10.1038/ejhg.2012.281.
-
(2013)
Eur. J. Hum. Genet
-
-
Chen, Y.1
Li, J.2
Yu, X.3
Li, S.4
Zhang, X.5
Mo, Z.6
Hu, Y.7
-
26
-
-
79951529502
-
Androgen hypersensitivity in prostate cancer: Molecular perspectives on androgen deprivation therapy strategies
-
Foley, R.; Marignol, L.; Keane, J.P.; Lynch, T.H.; Hollywood, D. Androgen hypersensitivity in prostate cancer: Molecular perspectives on androgen deprivation therapy strategies. Prostate 2010, 71, 550-557.
-
(2010)
Prostate
, vol.71
, pp. 550-557
-
-
Foley, R.1
Marignol, L.2
Keane, J.P.3
Lynch, T.H.4
Hollywood, D.5
-
27
-
-
79960071366
-
The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis
-
Massie, C.E.; Lynch, A.; Ramos-Montoya, A.; Boren, J.; Stark, R.; Fazli, L.; Warren, A.; Scott, H.; Madhu, B.; Sharma, N., et al. The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J. 2011, 30, 2719-2733.
-
(2011)
EMBO J
, vol.30
, pp. 2719-2733
-
-
Massie, C.E.1
Lynch, A.2
Ramos-Montoya, A.3
Boren, J.4
Stark, R.5
Fazli, L.6
Warren, A.7
Scott, H.8
Madhu, B.9
Sharma, N.10
-
28
-
-
79959312739
-
A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities
-
Hu, R.; Isaacs, W.B.; Luo, J. A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities. Prostate 2011, 71, 1656-1667.
-
(2011)
Prostate
, vol.71
, pp. 1656-1667
-
-
Hu, R.1
Isaacs, W.B.2
Luo, J.3
-
29
-
-
77958613785
-
Prioritizing genes associated with prostate cancer development
-
Gorlov, I.P.; Sircar, K.; Zhao, H.; Maity, S.N.; Navone, N.M.; Gorlova, O.Y.; Troncoso, P.; Pettaway, C.A.; Byun, J.Y.; Logothetis, C.J. Prioritizing genes associated with prostate cancer development. BMC Cancer 2010, 10, 599.
-
(2010)
BMC Cancer
, vol.10
, pp. 599
-
-
Gorlov, I.P.1
Sircar, K.2
Zhao, H.3
Maity, S.N.4
Navone, N.M.5
Gorlova, O.Y.6
Troncoso, P.7
Pettaway, C.A.8
Byun, J.Y.9
Logothetis, C.J.10
-
30
-
-
84866683064
-
Understanding the lethal variant of prostate cancer: Power of examining extremes
-
Aparicio, A.; Logothetis, C.J.; Maity, S.N. Understanding the lethal variant of prostate cancer: Power of examining extremes. Cancer Discov. 2011, 1, 466-468.
-
(2011)
Cancer Discov
, vol.1
, pp. 466-468
-
-
Aparicio, A.1
Logothetis, C.J.2
Maity, S.N.3
-
31
-
-
84873048485
-
Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer
-
Mosquera, J.M.; Beltran, H.; Park, K.; MacDonald, T.Y.; Robinson, B.D.; Tagawa, S.T.; Perner, S.; Bismar, T.A.; Erbersdobler, A.; Dhir, R., et al. Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. Neoplasia 2013, 15, 1-10.
-
(2013)
Neoplasia
, vol.15
, pp. 1-10
-
-
Mosquera, J.M.1
Beltran, H.2
Park, K.3
Macdonald, T.Y.4
Robinson, B.D.5
Tagawa, S.T.6
Perner, S.7
Bismar, T.A.8
Erbersdobler, A.9
Dhir, R.10
-
32
-
-
84876449854
-
Zinc alpha2-glycoprotein as a potential novel urine biomarker for the early diagnosis of prostate cancer
-
Katafigiotis, I.; Tyritzis, S.I.; Stravodimos, K.G.; Alamanis, C.; Pavlakis, K.; Vlahou, A.; Makridakis, M.; Katafigioti, A.; Garbis, S.D.; Constantinides, C.A. Zinc alpha2-glycoprotein as a potential novel urine biomarker for the early diagnosis of prostate cancer. BJU Int. 2012, 11, 688-693.
-
(2012)
BJU Int
, vol.11
, pp. 688-693
-
-
Katafigiotis, I.1
Tyritzis, S.I.2
Stravodimos, K.G.3
Alamanis, C.4
Pavlakis, K.5
Vlahou, A.6
Makridakis, M.7
Katafigioti, A.8
Garbis, S.D.9
Constantinides, C.A.10
-
33
-
-
80053210609
-
Low AZGP1 expression predicts for recurrence in margin-positive, localized prostate cancer
-
Yip, P.Y.; Kench, J.G.; Rasiah, K.K.; Benito, R.P.; Lee, C.S.; Stricker, P.D.; Henshall, S.M.; Sutherland, R.L.; Horvath, L.G. Low AZGP1 expression predicts for recurrence in margin-positive, localized prostate cancer. Prostate 2011, 71, 1638-1645.
-
(2011)
Prostate
, vol.71
, pp. 1638-1645
-
-
Yip, P.Y.1
Kench, J.G.2
Rasiah, K.K.3
Benito, R.P.4
Lee, C.S.5
Stricker, P.D.6
Henshall, S.M.7
Sutherland, R.L.8
Horvath, L.G.9
-
34
-
-
34147211128
-
LC-MS/MS quantification of Zn-alpha2 glycoprotein: A potential serum biomarker for prostate cancer
-
Bondar, O.P.; Barnidge, D.R.; Klee, E.W.; Davis, B.J.; Klee, G.G. LC-MS/MS quantification of Zn-alpha2 glycoprotein: A potential serum biomarker for prostate cancer. Clin. Chem. 2007, 53, 673-678.
-
(2007)
Clin. Chem
, vol.53
, pp. 673-678
-
-
Bondar, O.P.1
Barnidge, D.R.2
Klee, E.W.3
Davis, B.J.4
Klee, G.G.5
-
35
-
-
77954526989
-
Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma
-
Palanisamy, N.; Ateeq, B.; Kalyana-Sundaram, S.; Pflueger, D.; Ramnarayanan, K.; Shankar, S.; Han, B.; Cao, Q.; Cao, X.; Suleman, K., et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat. Med. 2010, 16, 793-798.
-
(2010)
Nat. Med
, vol.16
, pp. 793-798
-
-
Palanisamy, N.1
Ateeq, B.2
Kalyana-Sundaram, S.3
Pflueger, D.4
Ramnarayanan, K.5
Shankar, S.6
Han, B.7
Cao, Q.8
Cao, X.9
Suleman, K.10
-
36
-
-
84866424540
-
B-Raf activation cooperates with PTEN loss to drive c-Myc expression in advanced prostate cancer
-
Wang, J.; Kobayashi, T.; Floc'h, N.; Kinkade, C.W.; Aytes, A.; Dankort, D.; Lefebvre, C.; Mitrofanova, A.; Cardiff, R.D.; McMahon, M., et al. B-Raf activation cooperates with PTEN loss to drive c-Myc expression in advanced prostate cancer. Cancer Res. 2012, 72, 4765-4776.
-
(2012)
Cancer Res
, vol.72
, pp. 4765-4776
-
-
Wang, J.1
Kobayashi, T.2
Floc'H, N.3
Kinkade, C.W.4
Aytes, A.5
Dankort, D.6
Lefebvre, C.7
Mitrofanova, A.8
Cardiff, R.D.9
McMahon, M.10
-
37
-
-
84865996835
-
Identification of frequent BRAF copy number gain and alterations of RAF genes in Chinese prostate cancer
-
Ren, G.; Liu, X.; Mao, X.; Zhang, Y.; Stankiewicz, E.; Hylands, L.; Song, R.; Berney, D.M.; Clark, J.; Cooper, C., et al. Identification of frequent BRAF copy number gain and alterations of RAF genes in Chinese prostate cancer. Genes Chromosomes Cancer 2012, 51, 1014-1023.
-
(2012)
Genes Chromosomes Cancer
, vol.51
, pp. 1014-1023
-
-
Ren, G.1
Liu, X.2
Mao, X.3
Zhang, Y.4
Stankiewicz, E.5
Hylands, L.6
Song, R.7
Berney, D.M.8
Clark, J.9
Cooper, C.10
-
38
-
-
34347241757
-
Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles
-
Tamura, K.; Furihata, M.; Tsunoda, T.; Ashida, S.; Takata, R.; Obara, W.; Yoshioka, H.; Daigo, Y.; Nasu, Y.; Kumon, H., et al. Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles. Cancer Res. 2007, 67, 5117-5125.
-
(2007)
Cancer Res
, vol.67
, pp. 5117-5125
-
-
Tamura, K.1
Furihata, M.2
Tsunoda, T.3
Ashida, S.4
Takata, R.5
Obara, W.6
Yoshioka, H.7
Daigo, Y.8
Nasu, Y.9
Kumon, H.10
-
40
-
-
84867875624
-
Down-regulation of calcium/calmodulin-dependent protein kinase kinase 2 by androgen deprivation induces castration-resistant prostate cancer
-
Shima, T.; Mizokami, A.; Miyagi, T.; Kawai, K.; Izumi, K.; Kumaki, M.; Ofude, M.; Zhang, J.; Keller, E.T.; Namiki, M. Down-regulation of calcium/calmodulin-dependent protein kinase kinase 2 by androgen deprivation induces castration-resistant prostate cancer. Prostate 2012, 72, 1789-1801.
-
(2012)
Prostate
, vol.72
, pp. 1789-1801
-
-
Shima, T.1
Mizokami, A.2
Miyagi, T.3
Kawai, K.4
Izumi, K.5
Kumaki, M.6
Ofude, M.7
Zhang, J.8
Keller, E.T.9
Namiki, M.10
-
41
-
-
0028058712
-
Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer
-
Umbas, R.; Isaacs, W.B.; Bringuier, P.P.; Schaafsma, H.E.; Karthaus, H.F.; Oosterhof, G.O.; Debruyne, F.M.; Schalken, J.A. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res. 1994, 54, 3929-3933.
-
(1994)
Cancer Res
, vol.54
, pp. 3929-3933
-
-
Umbas, R.1
Isaacs, W.B.2
Bringuier, P.P.3
Schaafsma, H.E.4
Karthaus, H.F.5
Oosterhof, G.O.6
Debruyne, F.M.7
Schalken, J.A.8
-
42
-
-
0026795845
-
Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer
-
Umbas, R.; Schalken, J.A.; Aalders, T.W.; Carter, B.S.; Karthaus, H.F.; Schaafsma, H.E.; Debruyne, F.M.; Isaacs, W.B. Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res. 1992, 52, 5104-5109.
-
(1992)
Cancer Res
, vol.52
, pp. 5104-5109
-
-
Umbas, R.1
Schalken, J.A.2
Aalders, T.W.3
Carter, B.S.4
Karthaus, H.F.5
Schaafsma, H.E.6
Debruyne, F.M.7
Isaacs, W.B.8
-
43
-
-
58149391399
-
Custirsen (OGX-011): A second-generation antisense inhibitor of clusterin for the treatment of cancer
-
Chi, K.N.; Zoubeidi, A.; Gleave, M.E. Custirsen (OGX-011): A second-generation antisense inhibitor of clusterin for the treatment of cancer. Expert Opin. Investig Drugs 2008, 17, 1955-1962.
-
(2008)
Expert Opin. Investig Drugs
, vol.17
, pp. 1955-1962
-
-
Chi, K.N.1
Zoubeidi, A.2
Gleave, M.E.3
-
44
-
-
83455255600
-
The discovery of putative urine markers for the specific detection of prostate tumor by integrative mining of public genomic profiles
-
Chen, M.; Wang, K.; Zhang, L.; Li, C.; Yang, Y. The discovery of putative urine markers for the specific detection of prostate tumor by integrative mining of public genomic profiles. PLoS One 2011, 6, e28552.
-
(2011)
PLoS One
, vol.6
-
-
Chen, M.1
Wang, K.2
Zhang, L.3
Li, C.4
Yang, Y.5
-
45
-
-
84867117645
-
Exosomes as biomarker enriched microvesicles: Characterization of exosomal proteins derived from a panel of prostate cell lines with distinct AR phenotypes
-
Hosseini-Beheshti, E.; Pham, S.; Adomat, H.; Li, N.; Tomlinson Guns, E.S. Exosomes as biomarker enriched microvesicles: Characterization of exosomal proteins derived from a panel of prostate cell lines with distinct AR phenotypes. Mol. Cell Proteomics 2011, 11, 863-885.
-
(2011)
Mol. Cell Proteomics
, vol.11
, pp. 863-885
-
-
Hosseini-Beheshti, E.1
Pham, S.2
Adomat, H.3
Li, N.4
Tomlinson, G.E.S.5
-
46
-
-
80052256577
-
Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate-resistant prostate cancer
-
Lamoureux, F.; Thomas, C.; Yin, M.J.; Kuruma, H.; Beraldi, E.; Fazli, L.; Zoubeidi, A.; Gleave, M.E. Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate-resistant prostate cancer. Cancer Res. 2011, 71, 5838-5849.
-
(2011)
Cancer Res
, vol.71
, pp. 5838-5849
-
-
Lamoureux, F.1
Thomas, C.2
Yin, M.J.3
Kuruma, H.4
Beraldi, E.5
Fazli, L.6
Zoubeidi, A.7
Gleave, M.E.8
-
47
-
-
34547096244
-
Association of cysteine-rich secretory protein 3 and beta-microseminoprotein with outcome after radical prostatectomy
-
Bjartell, A.S.; Al-Ahmadie, H.; Serio, A.M.; Eastham, J.A.; Eggener, S.E.; Fine, S.W.; Udby, L.; Gerald, W.L.; Vickers, A.J.; Lilja, H., et al. Association of cysteine-rich secretory protein 3 and beta-microseminoprotein with outcome after radical prostatectomy. Clin. Cancer Res. 2007, 13, 4130-4138.
-
(2007)
Clin. Cancer Res
, vol.13
, pp. 4130-4138
-
-
Bjartell, A.S.1
Al-Ahmadie, H.2
Serio, A.M.3
Eastham, J.A.4
Eggener, S.E.5
Fine, S.W.6
Udby, L.7
Gerald, W.L.8
Vickers, A.J.9
Lilja, H.10
-
48
-
-
33645906530
-
Immunohistochemical detection of cysteine-rich secretory protein 3 in tissue and in serum from men with cancer or benign enlargement of the prostate gland
-
Bjartell, A.; Johansson, R.; Bjork, T.; Gadaleanu, V.; Lundwall, A.; Lilja, H.; Kjeldsen, L.; Udby, L. Immunohistochemical detection of cysteine-rich secretory protein 3 in tissue and in serum from men with cancer or benign enlargement of the prostate gland. Prostate 2006, 66, 591-603.
-
(2006)
Prostate
, vol.66
, pp. 591-603
-
-
Bjartell, A.1
Johansson, R.2
Bjork, T.3
Gadaleanu, V.4
Lundwall, A.5
Lilja, H.6
Kjeldsen, L.7
Udby, L.8
-
49
-
-
1642398202
-
Early identification of individuals with prostate cancer in negative biopsies
-
Dhir, R.; Vietmeier, B.; Arlotti, J.; Acquafondata, M.; Landsittel, D.; Masterson, R.; Getzenberg, R.H. Early identification of individuals with prostate cancer in negative biopsies. J. Urol. 2004, 171, 1419-1423.
-
(2004)
J. Urol
, vol.171
, pp. 1419-1423
-
-
Dhir, R.1
Vietmeier, B.2
Arlotti, J.3
Acquafondata, M.4
Landsittel, D.5
Masterson, R.6
Getzenberg, R.H.7
-
50
-
-
20144375228
-
Detection of prostate cancer with a blood-based assay for early prostate cancer antigen
-
Paul, B.; Dhir, R.; Landsittel, D.; Hitchens, M.R.; Getzenberg, R.H. Detection of prostate cancer with a blood-based assay for early prostate cancer antigen. Cancer Res. 2005, 65, 4097-4100.
-
(2005)
Cancer Res
, vol.65
, pp. 4097-4100
-
-
Paul, B.1
Dhir, R.2
Landsittel, D.3
Hitchens, M.R.4
Getzenberg, R.H.5
-
51
-
-
34147136783
-
EPCA-2: A highly specific serum marker for prostate cancer
-
Leman, E.S.; Cannon, G.W.; Trock, B.J.; Sokoll, L.J.; Chan, D.W.; Mangold, L.; Partin, A.W.; Getzenberg, R.H. EPCA-2: A highly specific serum marker for prostate cancer. Urology 2007, 69, 714-720.
-
(2007)
Urology
, vol.69
, pp. 714-720
-
-
Leman, E.S.1
Cannon, G.W.2
Trock, B.J.3
Sokoll, L.J.4
Chan, D.W.5
Mangold, L.6
Partin, A.W.7
Getzenberg, R.H.8
-
52
-
-
0023547004
-
Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
-
Horoszewicz, J.S.; Kawinski, E.; Murphy, G.P. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res. 1987, 7, 927-935.
-
(1987)
Anticancer Res
, vol.7
, pp. 927-935
-
-
Horoszewicz, J.S.1
Kawinski, E.2
Murphy, G.P.3
-
53
-
-
84876901422
-
Prostate specific membrane antigen (PSMA): A novel modulator of p38 for proliferation, migration, and survival in prostate cancer cells
-
Zhang, Y.; Guo, Z.; Du, T.; Chen, J.; Wang, W.; Xu, K.; Lin, T.; Huang, H. Prostate specific membrane antigen (PSMA): A novel modulator of p38 for proliferation, migration, and survival in prostate cancer cells. Prostate 2012, 73, 835-841.
-
(2012)
Prostate
, vol.73
, pp. 835-841
-
-
Zhang, Y.1
Guo, Z.2
Du, T.3
Chen, J.4
Wang, W.5
Xu, K.6
Lin, T.7
Huang, H.8
-
54
-
-
38849169937
-
A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer
-
Laxman, B.; Morris, D.S.; Yu, J.; Siddiqui, J.; Cao, J.; Mehra, R.; Lonigro, R.J.; Tsodikov, A.; Wei, J.T.; Tomlins, S.A., et al. M. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res. 2008, 68, 645-649.
-
(2008)
Cancer Res
, vol.68
, pp. 645-649
-
-
Laxman, B.1
Morris, D.S.2
Yu, J.3
Siddiqui, J.4
Cao, J.5
Mehra, R.6
Lonigro, R.J.7
Tsodikov, A.8
Wei, J.T.9
Tomlins, S.A.10
-
55
-
-
55849106651
-
Golgi protein GOLM1 is a tissue and urine biomarker of prostate cancer
-
Varambally, S.; Laxman, B.; Mehra, R.; Cao, Q.; Dhanasekaran, S.M.; Tomlins, S.A.; Granger, J.; Vellaichamy, A.; Sreekumar, A.; Yu, J., et al. Golgi protein GOLM1 is a tissue and urine biomarker of prostate cancer. Neoplasia 2008, 10, 1285-1294.
-
(2008)
Neoplasia
, vol.10
, pp. 1285-1294
-
-
Varambally, S.1
Laxman, B.2
Mehra, R.3
Cao, Q.4
Dhanasekaran, S.M.5
Tomlins, S.A.6
Granger, J.7
Vellaichamy, A.8
Sreekumar, A.9
Yu, J.10
-
56
-
-
1242318838
-
Detection of GSTP1 methylation in prostatic secretions using combinatorial MSP analysis
-
Gonzalgo, M.L.; Nakayama, M.; Lee, S.M.; de Marzo, A.M.; Nelson, W.G. Detection of GSTP1 methylation in prostatic secretions using combinatorial MSP analysis. Urology 2004, 63, 414-418.
-
(2004)
Urology
, vol.63
, pp. 414-418
-
-
Gonzalgo, M.L.1
Nakayama, M.2
Lee, S.M.3
de Marzo, A.M.4
Nelson, W.G.5
-
57
-
-
7444246683
-
Prostate cancer molecular markers GSTP1 and hTERT in expressed prostatic secretions as predictors of biopsy results
-
Crocitto, L.E.; Korns, D.; Kretzner, L.; Shevchuk, T.; Blair, S.L.; Wilson, T.G.; Ramin, S.A.; Kawachi, M.H.; Smith, S.S. Prostate cancer molecular markers GSTP1 and hTERT in expressed prostatic secretions as predictors of biopsy results. Urology 2004, 64, 821-825.
-
(2004)
Urology
, vol.64
, pp. 821-825
-
-
Crocitto, L.E.1
Korns, D.2
Kretzner, L.3
Shevchuk, T.4
Blair, S.L.5
Wilson, T.G.6
Ramin, S.A.7
Kawachi, M.H.8
Smith, S.S.9
-
58
-
-
10744220367
-
Hepsin is highly over expressed in and a new candidate for a prognostic indicator in prostate cancer
-
Stephan, C.; Yousef, G.M.; Scorilas, A.; Jung, K.; Jung, M.; Kristiansen, G.; Hauptmann, S.; Kishi, T.; Nakamura, T.; Loening, S.A., et al. Hepsin is highly over expressed in and a new candidate for a prognostic indicator in prostate cancer. J. Urol. 2004, 171, 187-191.
-
(2004)
J. Urol
, vol.17
, pp. 187-191
-
-
Stephan, C.1
Yousef, G.M.2
Scorilas, A.3
Jung, K.4
Jung, M.5
Kristiansen, G.6
Hauptmann, S.7
Kishi, T.8
Nakamura, T.9
Loening, S.A.10
-
59
-
-
0035939903
-
Delineation of prognostic biomarkers in prostate cancer
-
Dhanasekaran, S.M.; Barrette, T.R.; Ghosh, D.; Shah, R.; Varambally, S.; Kurachi, K.; Pienta, K.J.; Rubin, M.A.; Chinnaiyan, A.M. Delineation of prognostic biomarkers in prostate cancer. Nature 2001, 412, 822-826.
-
(2001)
Nature
, vol.412
, pp. 822-826
-
-
Dhanasekaran, S.M.1
Barrette, T.R.2
Ghosh, D.3
Shah, R.4
Varambally, S.5
Kurachi, K.6
Pienta, K.J.7
Rubin, M.A.8
Chinnaiyan, A.M.9
-
60
-
-
0035667565
-
Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis
-
Shariat, S.F.; Andrews, B.; Kattan, M.W.; Kim, J.; Wheeler, T.M.; Slawin, K.M. Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology 2001, 58, 1008-1015.
-
(2001)
Urology
, vol.58
, pp. 1008-1015
-
-
Shariat, S.F.1
Andrews, B.2
Kattan, M.W.3
Kim, J.4
Wheeler, T.M.5
Slawin, K.M.6
-
61
-
-
0033911711
-
Serum interleukin 6 as a prognostic factor in patients with prostate cancer
-
Nakashima, J.; Tachibana, M.; Horiguchi, Y.; Oya, M.; Ohigashi, T.; Asakura, H.; Murai, M. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin. Cancer Res. 2000, 6, 2702-2706.
-
(2000)
Clin. Cancer Res
, vol.6
, pp. 2702-2706
-
-
Nakashima, J.1
Tachibana, M.2
Horiguchi, Y.3
Oya, M.4
Ohigashi, T.5
Asakura, H.6
Murai, M.7
-
62
-
-
1642392553
-
Association of pre- and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression
-
Shariat, S.F.; Kattan, M.W.; Traxel, E.; Andrews, B.; Zhu, K.; Wheeler, T.M.; Slawin, K.M. Association of pre- and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression. Clin. Cancer Res. 2004, 10, 1992-1999.
-
(2004)
Clin. Cancer Res
, vol.10
, pp. 1992-1999
-
-
Shariat, S.F.1
Kattan, M.W.2
Traxel, E.3
Andrews, B.4
Zhu, K.5
Wheeler, T.M.6
Slawin, K.M.7
-
63
-
-
84867997051
-
Identification of novel serological tumor markers for human prostate cancer using integrative transcriptome and proteome analysis
-
Han, Z.D.; Zhang, Y.Q.; He, H.C.; Dai, Q.S.; Qin, G.Q.; Chen, J.H.; Cai, C.; Fu, X.; Bi, X.C.; Zhu, J.G., et al. Identification of novel serological tumor markers for human prostate cancer using integrative transcriptome and proteome analysis. Med. Oncol. 2012, 29, 2877-2888.
-
(2012)
Med. Oncol
, vol.29
, pp. 2877-2888
-
-
Han, Z.D.1
Zhang, Y.Q.2
He, H.C.3
Dai, Q.S.4
Qin, G.Q.5
Chen, J.H.6
Cai, C.7
Fu, X.8
Bi, X.C.9
Zhu, J.G.10
-
64
-
-
0030926344
-
Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: A novel prostate cancer marker
-
Darson, M.F.; Pacelli, A.; Roche, P.; Rittenhouse, H.G.; Wolfert, R.L.; Young, C.Y.; Klee, G.G.; Tindall, D.J.; Bostwick, D.G. Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: A novel prostate cancer marker. Urology 1997, 49, 857-862.
-
(1997)
Urology
, vol.49
, pp. 857-862
-
-
Darson, M.F.1
Pacelli, A.2
Roche, P.3
Rittenhouse, H.G.4
Wolfert, R.L.5
Young, C.Y.6
Klee, G.G.7
Tindall, D.J.8
Bostwick, D.G.9
-
65
-
-
0034791830
-
Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/mL
-
Haese, A.; Graefen, M.; Steuber, T.; Becker, C.; Pettersson, K.; Piironen, T.; Noldus, J.; Huland, H.; Lilja, H. Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/mL. Prostate 2001, 49, 101-109.
-
(2001)
Prostate
, vol.49
, pp. 101-109
-
-
Haese, A.1
Graefen, M.2
Steuber, T.3
Becker, C.4
Pettersson, K.5
Piironen, T.6
Noldus, J.7
Huland, H.8
Lilja, H.9
-
66
-
-
84873652789
-
PSA for prostate cancer detection: In serum, in urine or both
-
Aprikian, A. PSA for prostate cancer detection: In serum, in urine or both? Can. Urol. Assoc. J. 2007, 1, 382.
-
(2007)
Can. Urol. Assoc. J
, vol.1
, pp. 382
-
-
Aprikian, A.1
-
67
-
-
73449094567
-
Kallikrein-related peptidase-4 initiates tumor-stroma interactions in prostate cancer through protease-activated receptor-1
-
Wang, W.; Mize, G.J.; Zhang, X.; Takayama, T.K. Kallikrein-related peptidase-4 initiates tumor-stroma interactions in prostate cancer through protease-activated receptor-1. Int. J. Cancer 2010, 126, 599-610.
-
(2010)
Int. J. Cancer
, vol.126
, pp. 599-610
-
-
Wang, W.1
Mize, G.J.2
Zhang, X.3
Takayama, T.K.4
-
68
-
-
80054075544
-
Kallikrein-related peptidase 4 gene (KLK4) in prostate tumors: Quantitative expression analysis and evaluation of its clinical significance
-
Avgeris, M.; Stravodimos, K.; Scorilas, A. Kallikrein-related peptidase 4 gene (KLK4) in prostate tumors: Quantitative expression analysis and evaluation of its clinical significance. Prostate 2011, 71, 1780-1789.
-
(2011)
Prostate
, vol.71
, pp. 1780-1789
-
-
Avgeris, M.1
Stravodimos, K.2
Scorilas, A.3
-
69
-
-
74549136665
-
Differential expression of apoptotic genes PDIA3 and MAP3K5 distinguishes between low- and high-risk prostate cancer
-
Pressinotti, N.C.; Klocker, H.; Schafer, G.; Luu, V.D.; Ruschhaupt, M.; Kuner, R.; Steiner, E.; Poustka, A.; Bartsch, G.; Sultmann, H. Differential expression of apoptotic genes PDIA3 and MAP3K5 distinguishes between low- and high-risk prostate cancer. Mol. Cancer 2009, 8, 130.
-
(2009)
Mol. Cancer
, vol.8
, pp. 130
-
-
Pressinotti, N.C.1
Klocker, H.2
Schafer, G.3
Luu, V.D.4
Ruschhaupt, M.5
Kuner, R.6
Steiner, E.7
Poustka, A.8
Bartsch, G.9
Sultmann, H.10
-
70
-
-
0031689226
-
Ki67 labeling index in core needle biopsies independently predicts tumor-specific survival in prostate cancer
-
Bubendorf, L.; Tapia, C.; Gasser, T.C.; Casella, R.; Grunder, B.; Moch, H.; Mihatsch, M.J.; Sauter, G. Ki67 labeling index in core needle biopsies independently predicts tumor-specific survival in prostate cancer. Hum. Pathol. 1998, 29, 949-954.
-
(1998)
Hum. Pathol
, vol.29
, pp. 949-954
-
-
Bubendorf, L.1
Tapia, C.2
Gasser, T.C.3
Casella, R.4
Grunder, B.5
Moch, H.6
Mihatsch, M.J.7
Sauter, G.8
-
71
-
-
79952042778
-
Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: A retrospective study
-
Cuzick, J.; Swanson, G.P.; Fisher, G.; Brothman, A.R.; Berney, D.M.; Reid, J.E.; Mesher, D.; Speights, V.O.; Stankiewicz, E.; Foster, C.S., et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: A retrospective study. Lancet Oncol. 2009, 12, 245-255.
-
(2009)
Lancet Oncol
, vol.12
, pp. 245-255
-
-
Cuzick, J.1
Swanson, G.P.2
Fisher, G.3
Brothman, A.R.4
Berney, D.M.5
Reid, J.E.6
Mesher, D.7
Speights, V.O.8
Stankiewicz, E.9
Foster, C.S.10
-
72
-
-
63449084696
-
Tumor growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer
-
Zellweger, T.; Gunther, S.; Zlobec, I.; Savic, S.; Sauter, G.; Moch, H.; Mattarelli, G.; Eichenberger, T.; Curschellas, E.; Rufenacht, H., et al. Tumor growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer. Int. J. Cancer 2009, 124, 2116-2123.
-
(2009)
Int. J. Cancer
, vol.124
, pp. 2116-2123
-
-
Zellweger, T.1
Gunther, S.2
Zlobec, I.3
Savic, S.4
Sauter, G.5
Moch, H.6
Mattarelli, G.7
Eichenberger, T.8
Curschellas, E.9
Rufenacht, H.10
-
73
-
-
22044445706
-
Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues
-
Riddick, A.C.; Shukla, C.J.; Pennington, C.J.; Bass, R.; Nuttall, R.K.; Hogan, A.; Sethia, K.K.; Ellis, V.; Collins, A.T.; Maitland, N.J., et al. Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues. Br. J. Cancer 2005, 92, 2171-2180.
-
(2005)
Br. J. Cancer
, vol.92
, pp. 2171-2180
-
-
Riddick, A.C.1
Shukla, C.J.2
Pennington, C.J.3
Bass, R.4
Nuttall, R.K.5
Hogan, A.6
Sethia, K.K.7
Ellis, V.8
Collins, A.T.9
Maitland, N.J.10
-
74
-
-
33748712425
-
Coordinated peak expression of MMP-26 and TIMP-4 in preinvasive human prostate tumor
-
Lee, S.; Desai, K.K.; Iczkowski, K.A.; Newcomer, R.G.; Wu, K.J.; Zhao, Y.G.; Tan, W.W.; Roycik, M.D.; Sang, Q.X. Coordinated peak expression of MMP-26 and TIMP-4 in preinvasive human prostate tumor. Cell Res. 2006, 16, 750-758.
-
(2006)
Cell Res
, vol.16
, pp. 750-758
-
-
Lee, S.1
Desai, K.K.2
Iczkowski, K.A.3
Newcomer, R.G.4
Wu, K.J.5
Zhao, Y.G.6
Tan, W.W.7
Roycik, M.D.8
Sang, Q.X.9
-
75
-
-
39449136559
-
Laser-capture microdissection in prostate cancer research: Establishment and validation of a powerful tool for the assessment of tumor-stroma interactions
-
Shukla, C.J.; Pennington, C.J.; Riddick, A.C.; Sethia, K.K.; Ball, R.Y.; Edwards, D.R. Laser-capture microdissection in prostate cancer research: Establishment and validation of a powerful tool for the assessment of tumor-stroma interactions. BJU Int. 2008, 101, 765-74.
-
(2008)
BJU Int
, vol.101
, pp. 765-774
-
-
Shukla, C.J.1
Pennington, C.J.2
Riddick, A.C.3
Sethia, K.K.4
Ball, R.Y.5
Edwards, D.R.6
-
76
-
-
85044708652
-
Expression of matrix metalloproteinase-26 in multiple human cancer tissues and smooth muscle cells
-
Zhao, Y.G.; Xiao, A.Z.; Ni, J.; Man, Y.G.; Sang, Q.X. Expression of matrix metalloproteinase-26 in multiple human cancer tissues and smooth muscle cells. Ai Zheng 2009, 28, 1168-1175.
-
(2009)
Ai Zheng
, vol.28
, pp. 1168-1175
-
-
Zhao, Y.G.1
Xiao, A.Z.2
Ni, J.3
Man, Y.G.4
Sang, Q.X.5
-
77
-
-
0032054579
-
Increased incidence of matrix metalloproteinases in urine of cancer patients
-
Moses, M.A.; Wiederschain, D.; Loughlin, K.R.; Zurakowski, D.; Lamb, C.C.; Freeman, M.R. Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res. 1998, 58, 1395-1399.
-
(1998)
Cancer Res
, vol.58
, pp. 1395-1399
-
-
Moses, M.A.1
Wiederschain, D.2
Loughlin, K.R.3
Zurakowski, D.4
Lamb, C.C.5
Freeman, M.R.6
-
78
-
-
58049203639
-
Tumor-specific urinary matrix metalloproteinase fingerprinting: Identification of high molecular weight urinary matrix metalloproteinase species
-
Roy, R.; Louis, G.; Loughlin, K.R.; Wiederschain, D.; Kilroy, S.M.; Lamb, C.C.; Zurakowski, D.; Moses, M.A. Tumor-specific urinary matrix metalloproteinase fingerprinting: Identification of high molecular weight urinary matrix metalloproteinase species. Clin. Cancer Res. 2008, 14, 6610-6617.
-
(2008)
Clin. Cancer Res
, vol.14
, pp. 6610-6617
-
-
Roy, R.1
Louis, G.2
Loughlin, K.R.3
Wiederschain, D.4
Kilroy, S.M.5
Lamb, C.C.6
Zurakowski, D.7
Moses, M.A.8
-
79
-
-
0034547945
-
PSGR, a novel prostate-specific gene with homology to a G protein-coupled receptor, is overexpressed in prostate cancer
-
Xu, L.L.; Stackhouse, B.G.; Florence, K.; Zhang, W.; Shanmugam, N.; Sesterhenn, I.A.; Zou, Z.; Srikantan, V.; Augustus, M.; Roschke, V., et al. PSGR, a novel prostate-specific gene with homology to a G protein-coupled receptor, is overexpressed in prostate cancer. Cancer Res. 2000, 60, 6568-6572.
-
(2000)
Cancer Res
, vol.60
, pp. 6568-6572
-
-
Xu, L.L.1
Stackhouse, B.G.2
Florence, K.3
Zhang, W.4
Shanmugam, N.5
Sesterhenn, I.A.6
Zou, Z.7
Srikantan, V.8
Augustus, M.9
Roschke, V.10
-
80
-
-
33644920405
-
Quantitative expression profile of PSGR in prostate cancer
-
Xu, L.L.; Sun, C.; Petrovics, G.; Makarem, M.; Furusato, B.; Zhang, W.; Sesterhenn, I.A.; McLeod, D.G.; Sun, L.; Moul, J.W., et al. Quantitative expression profile of PSGR in prostate cancer. Prostate Cancer Prostatic Dis. 2006, 9, 56-61.
-
(2006)
Prostate Cancer Prostatic Dis
, vol.9
, pp. 56-61
-
-
Xu, L.L.1
Sun, C.2
Petrovics, G.3
Makarem, M.4
Furusato, B.5
Zhang, W.6
Sesterhenn, I.A.7
McLeod, D.G.8
Sun, L.9
Moul, J.W.10
-
81
-
-
78349262391
-
PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine
-
Rigau, M.; Morote, J.; Mir, M.C.; Ballesteros, C.; Ortega, I.; Sanchez, A.; Colas, E.; Garcia, M.; Ruiz, A.; Abal, M., et al. PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine. Prostate 2010, 70, 1760-1767.
-
(2010)
Prostate
, vol.70
, pp. 1760-1767
-
-
Rigau, M.1
Morote, J.2
Mir, M.C.3
Ballesteros, C.4
Ortega, I.5
Sanchez, A.6
Colas, E.7
Garcia, M.8
Ruiz, A.9
Abal, M.10
-
82
-
-
0014239107
-
The development of the acid phosphatase test for prostatic carcinoma: The Sixth Ferdinand C. Valentine Memorial Lecture
-
Gutman, A.B. The development of the acid phosphatase test for prostatic carcinoma: The Sixth Ferdinand C. Valentine Memorial Lecture. Bull. N. Y. Acad. Med. 1968, 44, 63-76.
-
(1968)
Bull. N. Y. Acad. Med
, vol.44
, pp. 63-76
-
-
Gutman, A.B.1
-
83
-
-
84870679496
-
Identification of differentially expressed proteins in direct expressed prostatic secretions of men with organ-confined versus extracapsular prostate cancer
-
Kim, Y.; Ignatchenko, V.; Yao, C.Q.; Kalatskaya, I.; Nyalwidhe, J.O.; Lance, R.S.; Gramolini, A.O.; Troyer, D.A.; Stein, L.D.; Boutros, P.C., et al. Identification of differentially expressed proteins in direct expressed prostatic secretions of men with organ-confined versus extracapsular prostate cancer. Mol. Cell Proteomics 2012, 11, 1870-1884.
-
(2012)
Mol. Cell Proteomics
, vol.11
, pp. 1870-1884
-
-
Kim, Y.1
Ignatchenko, V.2
Yao, C.Q.3
Kalatskaya, I.4
Nyalwidhe, J.O.5
Lance, R.S.6
Gramolini, A.O.7
Troyer, D.A.8
Stein, L.D.9
Boutros, P.C.10
-
84
-
-
84895065530
-
Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer
-
doi:10.1016/j.eururo.2012.11.014
-
Leyten, G.H.; Hessels, D.; Jannink, S.A.; Smit, F.P.; de Jong, H.; Cornel, E.B.; de Reijke, T.M.; Vergunst, H.; Kil, P.; Knipscheer, B.C., et al. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur. Urol. 2012, doi:10.1016/j.eururo.2012.11.014.
-
(2012)
Eur. Urol
-
-
Leyten, G.H.1
Hessels, D.2
Jannink, S.A.3
Smit, F.P.4
de Jong, H.5
Cornel, E.B.6
de Reijke, T.M.7
Vergunst, H.8
Kil, P.9
Knipscheer, B.C.10
-
85
-
-
0033429470
-
DD3: A new prostate-specific gene, highly overexpressed in prostate cancer
-
Bussemakers, M.J.; van Bokhoven, A.; Verhaegh, G.W.; Smit, F.P.; Karthaus, H.F.; Schalken, J.A.; Debruyne, F.M.; Ru, N.; Isaacs, W.B. DD3: A new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999, 59, 5975-5979.
-
(1999)
Cancer Res
, vol.5
, pp. 5975-5979
-
-
Bussemakers, M.J.1
van Bokhoven, A.2
Verhaegh, G.W.3
Smit, F.P.4
Karthaus, H.F.5
Schalken, J.A.6
Debruyne, F.M.7
Ru, N.8
Isaacs, W.B.9
-
86
-
-
78650533827
-
PCA3: From basic molecular science to the clinical lab
-
Day, J.R.; Jost, M.; Reynolds, M.A.; Groskopf, J.; Rittenhouse, H. PCA3: From basic molecular science to the clinical lab. Cancer Lett. 2011, 301, 1-6.
-
(2011)
Cancer Lett
, vol.301
, pp. 1-6
-
-
Day, J.R.1
Jost, M.2
Reynolds, M.A.3
Groskopf, J.4
Rittenhouse, H.5
-
87
-
-
70449533255
-
The use of PCA3 in the diagnosis of prostate cancer
-
Hessels, D.; Schalken, J.A. The use of PCA3 in the diagnosis of prostate cancer. Nat. Rev. Urol. 2009, 6, 255-261.
-
(2009)
Nat. Rev. Urol
, vol.6
, pp. 255-261
-
-
Hessels, D.1
Schalken, J.A.2
-
88
-
-
0037974513
-
DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer
-
discussion 15-16
-
Hessels, D.; Klein Gunnewiek, J.M.; van Oort, I.; Karthaus, H.F.; van Leenders, G.J.; van Balken, B.; Kiemeney, L.A.; Witjes, J.A.; Schalken, J.A. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur. Urol. 2003, 44, 8-15; discussion 15-16.
-
(2003)
Eur. Urol
, vol.44
, pp. 8-15
-
-
Hessels, D.1
Klein, G.J.M.2
van Oort, I.3
Karthaus, H.F.4
van Leenders, G.J.5
van Balken, B.6
Kiemeney, L.A.7
Witjes, J.A.8
Schalken, J.A.9
-
89
-
-
33847397812
-
The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance
-
Van Gils, M.P.; Hessels, D.; van Hooij, O.; Jannink, S.A.; Peelen, W.P.; Hanssen, S.L.; Witjes, J.A.; Cornel, E.B.; Karthaus, H.F.; Smits, G.A., et al. The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. Clin. Cancer Res. 2007, 13, 939-943.
-
(2007)
Clin. Cancer Res
, vol.13
, pp. 939-943
-
-
van Gils, M.P.1
Hessels, D.2
van Hooij, O.3
Jannink, S.A.4
Peelen, W.P.5
Hanssen, S.L.6
Witjes, J.A.7
Cornel, E.B.8
Karthaus, H.F.9
Smits, G.A.10
-
90
-
-
33646942410
-
APTIMA PCA3 molecular urine test: Development of a method to aid in the diagnosis of prostate cancer
-
Groskopf, J.; Aubin, S.M.; Deras, I.L.; Blase, A.; Bodrug, S.; Clark, C.; Brentano, S.; Mathis, J.; Pham, J.; Meyer, T., et al. APTIMA PCA3 molecular urine test: Development of a method to aid in the diagnosis of prostate cancer. Clin. Chem. 2006, 52, 1089-1095.
-
(2006)
Clin. Chem
, vol.52
, pp. 1089-1095
-
-
Groskopf, J.1
Aubin, S.M.2
Deras, I.L.3
Blase, A.4
Bodrug, S.5
Clark, C.6
Brentano, S.7
Mathis, J.8
Pham, J.9
Meyer, T.10
-
91
-
-
40849087631
-
PCA3: A molecular urine assay for predicting prostate biopsy outcome
-
Deras, I.L.; Aubin, S.M.; Blase, A.; Day, J.R.; Koo, S.; Partin, A.W.; Ellis, W.J.; Marks, L.S.; Fradet, Y.; Rittenhouse, H., et al. PCA3: A molecular urine assay for predicting prostate biopsy outcome. J. Urol. 2008, 179, 1587-1592.
-
(2008)
J. Urol
, vol.179
, pp. 1587-1592
-
-
Deras, I.L.1
Aubin, S.M.2
Blase, A.3
Day, J.R.4
Koo, S.5
Partin, A.W.6
Ellis, W.J.7
Marks, L.S.8
Fradet, Y.9
Rittenhouse, H.10
-
92
-
-
79551478699
-
Prostate cancer antigen 3 score accurately predicts tumor volume and might help in selecting prostate cancer patients for active surveillance
-
Ploussard, G.; Durand, X.; Xylinas, E.; Moutereau, S.; Radulescu, C.; Forgue, A.; Nicolaiew, N.; Terry, S.; Allory, Y.; Loric, S., et al. Prostate cancer antigen 3 score accurately predicts tumor volume and might help in selecting prostate cancer patients for active surveillance. Eur. Urol. 2011, 59, 422-429.
-
(2011)
Eur. Urol
, vol.59
, pp. 422-429
-
-
Ploussard, G.1
Durand, X.2
Xylinas, E.3
Moutereau, S.4
Radulescu, C.5
Forgue, A.6
Nicolaiew, N.7
Terry, S.8
Allory, Y.9
Loric, S.10
-
93
-
-
34249685906
-
Molecular PCA3 diagnostics on prostatic fluid
-
Van Gils, M.P.; Cornel, E.B.; Hessels, D.; Peelen, W.P.; Witjes, J.A.; Mulders, P.F.; Rittenhouse, H.G.; Schalken, J.A. Molecular PCA3 diagnostics on prostatic fluid. Prostate 2007, 67, 881-887.
-
(2007)
Prostate
, vol.67
, pp. 881-887
-
-
van Gils, M.P.1
Cornel, E.B.2
Hessels, D.3
Peelen, W.P.4
Witjes, J.A.5
Mulders, P.F.6
Rittenhouse, H.G.7
Schalken, J.A.8
-
94
-
-
0034594917
-
Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer
-
Gu, Z.; Thomas, G.; Yamashiro, J.; Shintaku, I.P.; Dorey, F.; Raitano, A.; Witte, O.N.; Said, J.W.; Loda, M.; Reiter, R.E. Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene 2000, 19, 1288-1296.
-
(2000)
Oncogene
, vol.19
, pp. 1288-1296
-
-
Gu, Z.1
Thomas, G.2
Yamashiro, J.3
Shintaku, I.P.4
Dorey, F.5
Raitano, A.6
Witte, O.N.7
Said, J.W.8
Loda, M.9
Reiter, R.E.10
-
95
-
-
27144471037
-
Anti-prostate stem cell antigen monoclonal antibody 1G8 induces cell death in vitro and inhibits tumor growth in vivo via a Fc-independent mechanism
-
Gu, Z.; Yamashiro, J.; Kono, E.; Reiter, R.E. Anti-prostate stem cell antigen monoclonal antibody 1G8 induces cell death in vitro and inhibits tumor growth in vivo via a Fc-independent mechanism. Cancer Res. 2005, 65, 9495-9500.
-
(2005)
Cancer Res
, vol.65
, pp. 9495-9500
-
-
Gu, Z.1
Yamashiro, J.2
Kono, E.3
Reiter, R.E.4
-
96
-
-
84856743589
-
Prognostic value of promoter hypermethylation of retinoic acid receptor beta (RARB) and CDKN2 (p16/MTS1) in prostate cancer
-
Ameri, A.; Alidoosti, A.; Hosseini, S.Y.; Parvin, M.; Emranpour, M.H.; Taslimi, F.; Salehi, E.; Fadavip, P. Prognostic value of promoter hypermethylation of retinoic acid receptor beta (RARB) and CDKN2 (p16/MTS1) in prostate cancer. Chin. J. Cancer Res. 2011, 23, 306-311.
-
(2011)
Chin. J. Cancer Res
, vol.23
, pp. 306-311
-
-
Ameri, A.1
Alidoosti, A.2
Hosseini, S.Y.3
Parvin, M.4
Emranpour, M.H.5
Taslimi, F.6
Salehi, E.7
Fadavip, P.8
-
97
-
-
80053294761
-
Frequent methylation of RASSF1 and RARB in urine sediments from patients with early stage prostate cancer
-
Daniunaite, K.; Berezniakovas, A.; Jankevicius, F.; Laurinavicius, A.; Lazutka, J.R.; Jarmalaite, S. Frequent methylation of RASSF1 and RARB in urine sediments from patients with early stage prostate cancer. Medicina (Kaunas) 2011, 47, 147-153.
-
(2011)
Medicina (Kaunas)
, vol.47
, pp. 147-153
-
-
Daniunaite, K.1
Berezniakovas, A.2
Jankevicius, F.3
Laurinavicius, A.4
Lazutka, J.R.5
Jarmalaite, S.6
-
98
-
-
60149091657
-
Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression
-
Sreekumar, A.; Poisson, L.M.; Rajendiran, T.M.; Khan, A.P.; Cao, Q.; Yu, J.; Laxman, B.; Mehra, R.; Lonigro, R.J.; Li, Y., et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009, 457, 910-914.
-
(2009)
Nature
, vol.457
, pp. 910-914
-
-
Sreekumar, A.1
Poisson, L.M.2
Rajendiran, T.M.3
Khan, A.P.4
Cao, Q.5
Yu, J.6
Laxman, B.7
Mehra, R.8
Lonigro, R.J.9
Li, Y.10
-
99
-
-
44449139593
-
The role of SPINK1 in ETS rearrangement-negative prostate cancers
-
Tomlins, S.A.; Rhodes, D.R.; Yu, J.; Varambally, S.; Mehra, R.; Perner, S.; Demichelis, F.; Helgeson, B.E.; Laxman, B.; Morris, D.S., et al. The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell. 2008, 13, 519-528.
-
(2008)
Cancer Cell
, vol.13
, pp. 519-528
-
-
Tomlins, S.A.1
Rhodes, D.R.2
Yu, J.3
Varambally, S.4
Mehra, R.5
Perner, S.6
Demichelis, F.7
Helgeson, B.E.8
Laxman, B.9
Morris, D.S.10
-
100
-
-
0035047078
-
The use of telomerase activity for the detection of prostatic cancer cells after prostatic massage
-
Meid, F.H.; Gygi, C.M.; Leisinger, H.J.; Bosman, F.T.; Benhattar, J. The use of telomerase activity for the detection of prostatic cancer cells after prostatic massage. J. Urol. 2001, 165, 1802-1805.
-
(2001)
J. Urol
, vol.165
, pp. 1802-1805
-
-
Meid, F.H.1
Gygi, C.M.2
Leisinger, H.J.3
Bosman, F.T.4
Benhattar, J.5
-
101
-
-
84861422497
-
Plasma hTERT mRNA discriminates between clinically localized and locally advanced disease and is a predictor of recurrence in prostate cancer patients
-
March-Villalba, J.A.; Martinez-Jabaloyas, J.M.; Herrero, M.J.; Santamaria, J.; Alino, S.F.; Dasi, F. Plasma hTERT mRNA discriminates between clinically localized and locally advanced disease and is a predictor of recurrence in prostate cancer patients. Expert Opin. Biol. Ther. 2012, 12, S69-S77.
-
(2012)
Expert Opin. Biol. Ther
, vol.12
-
-
March-Villalba, J.A.1
Martinez-Jabaloyas, J.M.2
Herrero, M.J.3
Santamaria, J.4
Alino, S.F.5
Dasi, F.6
-
102
-
-
40849099826
-
Early postoperative plasma transforming growth factor-beta1 is a strong predictor of biochemical progression after radical prostatectomy
-
Shariat, S.F.; Walz, J.; Roehrborn, C.G.; Montorsi, F.; Jeldres, C.; Saad, F.; Karakiewicz, P.I. Early postoperative plasma transforming growth factor-beta1 is a strong predictor of biochemical progression after radical prostatectomy. J. Urol. 2008, 179, 1593-1597.
-
(2008)
J. Urol
, vol.179
, pp. 1593-1597
-
-
Shariat, S.F.1
Walz, J.2
Roehrborn, C.G.3
Montorsi, F.4
Jeldres, C.5
Saad, F.6
Karakiewicz, P.I.7
-
103
-
-
0028902318
-
Elevated plasma levels of TGF-beta 1 in patients with invasive prostate cancer
-
Ivanovic, V.; Melman, A.; Davis-Joseph, B.; Valcic, M.; Geliebter, J. Elevated plasma levels of TGF-beta 1 in patients with invasive prostate cancer. Nat. Med. 1995, 1, 282-284.
-
(1995)
Nat. Med
, vol.1
, pp. 282-284
-
-
Ivanovic, V.1
Melman, A.2
Davis-Joseph, B.3
Valcic, M.4
Geliebter, J.5
-
104
-
-
34548863661
-
Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer
-
Hessels, D.; Smit, F.P.; Verhaegh, G.W.; Witjes, J.A.; Cornel, E.B.; Schalken, J.A. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin. Cancer Res. 2007, 13, 5103-5108.
-
(2007)
Clin. Cancer Res
, vol.13
, pp. 5103-5108
-
-
Hessels, D.1
Smit, F.P.2
Verhaegh, G.W.3
Witjes, J.A.4
Cornel, E.B.5
Schalken, J.A.6
-
105
-
-
27344451557
-
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer
-
Tomlins, S.A.; Rhodes, D.R.; Perner, S.; Dhanasekaran, S.M.; Mehra, R.; Sun, X.W.; Varambally, S.; Cao, X.; Tchinda, J.; Kuefer, R., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005, 310, 644-648.
-
(2005)
Science
, vol.310
, pp. 644-648
-
-
Tomlins, S.A.1
Rhodes, D.R.2
Perner, S.3
Dhanasekaran, S.M.4
Mehra, R.5
Sun, X.W.6
Varambally, S.7
Cao, X.8
Tchinda, J.9
Kuefer, R.10
-
106
-
-
68049101459
-
Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States
-
Mosquera, J.M.; Mehra, R.; Regan, M.M.; Perner, S.; Genega, E.M.; Bueti, G.; Shah, R.B.; Gaston, S.; Tomlins, S.A.; Wei, J.T., et al. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin. Cancer Res. 2009, 15, 4706-4711.
-
(2009)
Clin. Cancer Res
, vol.15
, pp. 4706-4711
-
-
Mosquera, J.M.1
Mehra, R.2
Regan, M.M.3
Perner, S.4
Genega, E.M.5
Bueti, G.6
Shah, R.B.7
Gaston, S.8
Tomlins, S.A.9
Wei, J.T.10
-
107
-
-
0034219455
-
Expression of soluble urokinase plasminogen activator receptor may be related to outcome in prostate cancer patients
-
McCabe, N.P.; Angwafo, F.F., III; Zaher, A.; Selman, S.H.; Kouinche, A.; Jankun, J. Expression of soluble urokinase plasminogen activator receptor may be related to outcome in prostate cancer patients. Oncol. Rep. 2000, 7, 879-882.
-
(2000)
Oncol. Rep
, vol.7
, pp. 879-882
-
-
McCabe, N.P.1
Angwafo III, F.F.2
Zaher, A.3
Selman, S.H.4
Kouinche, A.5
Jankun, J.6
-
108
-
-
33846978442
-
Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis
-
Shariat, S.F.; Roehrborn, C.G.; McConnell, J.D.; Park, S.; Alam, N.; Wheeler, T.M.; Slawin, K.M. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J. Clin. Oncol. 2007, 25, 349-355.
-
(2007)
J. Clin. Oncol
, vol.25
, pp. 349-355
-
-
Shariat, S.F.1
Roehrborn, C.G.2
McConnell, J.D.3
Park, S.4
Alam, N.5
Wheeler, T.M.6
Slawin, K.M.7
-
109
-
-
28544446695
-
Biomarkers in cancer staging, prognosis and treatment selection
-
Ludwig, J.A.; Weinstein, J.N. Biomarkers in cancer staging, prognosis and treatment selection. Nat. Rev. Cancer 2005, 5, 845-856.
-
(2005)
Nat. Rev. Cancer
, vol.5
, pp. 845-856
-
-
Ludwig, J.A.1
Weinstein, J.N.2
-
110
-
-
34250172748
-
Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage
-
Roupret, M.; Hupertan, V.; Yates, D.R.; Catto, J.W.; Rehman, I.; Meuth, M.; Ricci, S.; Lacave, R.; Cancel-Tassin, G.; de la Taille, A., et al. Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage. Clin. Cancer Res. 2007, 13, 1720-1725.
-
(2007)
Clin. Cancer Res
, vol.13
, pp. 1720-1725
-
-
Roupret, M.1
Hupertan, V.2
Yates, D.R.3
Catto, J.W.4
Rehman, I.5
Meuth, M.6
Ricci, S.7
Lacave, R.8
Cancel-Tassin, G.9
de la Taille, A.10
-
111
-
-
3843106187
-
GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer
-
Nakayama, M.; Gonzalgo, M.L.; Yegnasubramanian, S.; Lin, X.; de Marzo, A.M.; Nelson, W.G. GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer. J. Cell Biochem. 2004, 91, 540-552.
-
(2004)
J. Cell Biochem
, vol.91
, pp. 540-552
-
-
Nakayama, M.1
Gonzalgo, M.L.2
Yegnasubramanian, S.3
Lin, X.4
de Marzo, A.M.5
Nelson, W.G.6
-
112
-
-
27244450828
-
Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects
-
Hoque, M.O.; Topaloglu, O.; Begum, S.; Henrique, R.; Rosenbaum, E.; van Criekinge, W.; Westra, W.H.; Sidransky, D. Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J. Clin. Oncol. 2005, 23, 6569-6575.
-
(2005)
J. Clin. Oncol
, vol.23
, pp. 6569-6575
-
-
Hoque, M.O.1
Topaloglu, O.2
Begum, S.3
Henrique, R.4
Rosenbaum, E.5
van Criekinge, W.6
Westra, W.H.7
Sidransky, D.8
-
113
-
-
80052585520
-
TCF21 and PCDH17 methylation: An innovative panel of biomarkers for a simultaneous detection of urological cancers
-
Costa, V.L.; Henrique, R.; Danielsen, S.A.; Eknaes, M.; Patricio, P.; Morais, A.; Oliveira, J.; Lothe, R.A.; Teixeira, M.R.; Lind, G.E., et al. TCF21 and PCDH17 methylation: An innovative panel of biomarkers for a simultaneous detection of urological cancers. Epigenetics 2011, 6, 1120-1130.
-
(2011)
Epigenetics
, vol.6
, pp. 1120-1130
-
-
Costa, V.L.1
Henrique, R.2
Danielsen, S.A.3
Eknaes, M.4
Patricio, P.5
Morais, A.6
Oliveira, J.7
Lothe, R.A.8
Teixeira, M.R.9
Lind, G.E.10
-
114
-
-
0033400445
-
Prostate-specific membrane antigen levels in sera from healthy men and patients with benign prostate hyperplasia or prostate cancer
-
Beckett, M.L.; Cazares, L.H.; Vlahou, A.; Schellhammer, P.F.; Wright, G.L., Jr. Prostate-specific membrane antigen levels in sera from healthy men and patients with benign prostate hyperplasia or prostate cancer. Clin. Cancer Res. 1999, 5, 4034-4040.
-
(1999)
Clin. Cancer Res
, vol.5
, pp. 4034-4040
-
-
Beckett, M.L.1
Cazares, L.H.2
Vlahou, A.3
Schellhammer, P.F.4
Wright Jr., G.L.5
-
115
-
-
0034003421
-
A dual-monoclonal sandwich assay for prostate-specific membrane antigen: Levels in tissues, seminal fluid and urine
-
Sokoloff, R.L.; Norton, K.C.; Gasior, C.L.; Marker, K.M.; Grauer, L.S. A dual-monoclonal sandwich assay for prostate-specific membrane antigen: Levels in tissues, seminal fluid and urine. Prostate 2000, 43, 150-157.
-
(2000)
Prostate
, vol.43
, pp. 150-157
-
-
Sokoloff, R.L.1
Norton, K.C.2
Gasior, C.L.3
Marker, K.M.4
Grauer, L.S.5
-
116
-
-
0035881634
-
Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease
-
Xiao, Z.; Adam, B.L.; Cazares, L.H.; Clements, M.A.; Davis, J.W.; Schellhammer, P.F.; Dalmasso, E.A.; Wright, G.L., Jr. Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. Cancer Res. 2001, 61, 6029-6033.
-
(2001)
Cancer Res
, vol.61
, pp. 6029-6033
-
-
Xiao, Z.1
Adam, B.L.2
Cazares, L.H.3
Clements, M.A.4
Davis, J.W.5
Schellhammer, P.F.6
Dalmasso, E.A.7
Wright Jr., G.L.8
-
117
-
-
76749149154
-
Diagnostic potential in prostate cancer of a panel of urinary molecular tumor markers
-
Talesa, V.N.; Antognelli, C.; del Buono, C.; Stracci, F.; Serva, M.R.; Cottini, E.; Mearini, E. Diagnostic potential in prostate cancer of a panel of urinary molecular tumor markers. Cancer Biomark 2009, 5, 241-251.
-
(2009)
Cancer Biomark
, vol.5
, pp. 241-251
-
-
Talesa, V.N.1
Antognelli, C.2
del Buono, C.3
Stracci, F.4
Serva, M.R.5
Cottini, E.6
Mearini, E.7
-
118
-
-
60549099598
-
Can urinary exosomes act as treatment response markers in prostate cancer?
-
Mitchell, P.J.; Welton, J.; Staffurth, J.; Court, J.; Mason, M.D.; Tabi, Z.; Clayton, A. Can urinary exosomes act as treatment response markers in prostate cancer? J. Transl. Med. 2009, 7, 4.
-
(2009)
J. Transl. Med
, vol.7
, pp. 4
-
-
Mitchell, P.J.1
Welton, J.2
Staffurth, J.3
Court, J.4
Mason, M.D.5
Tabi, Z.6
Clayton, A.7
-
119
-
-
80054071714
-
A Three-Gene panel on urine increases PSA specificity in the detection of prostate cancer
-
Rigau, M.; Ortega, I.; Mir, M.C.; Ballesteros, C.; Garcia, M.; Llaurado, M.; Colas, E.; Pedrola, N.; Montes, M.; Sequeiros, T., et al. A Three-Gene panel on urine increases PSA specificity in the detection of prostate cancer. Prostate 2011, 71, 1736-1745.
-
(2011)
Prostate
, vol.71
, pp. 1736-1745
-
-
Rigau, M.1
Ortega, I.2
Mir, M.C.3
Ballesteros, C.4
Garcia, M.5
Llaurado, M.6
Colas, E.7
Pedrola, N.8
Montes, M.9
Sequeiros, T.10
-
120
-
-
79951548592
-
TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients
-
Magi-Galluzzi, C.; Tsusuki, T.; Elson, P.; Simmerman, K.; LaFargue, C.; Esgueva, R.; Klein, E.; Rubin, M.A.; Zhou, M. TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients. Prostate 2011, 71, 489-497.
-
(2011)
Prostate
, vol.71
, pp. 489-497
-
-
Magi-Galluzzi, C.1
Tsusuki, T.2
Elson, P.3
Simmerman, K.4
Lafargue, C.5
Esgueva, R.6
Klein, E.7
Rubin, M.A.8
Zhou, M.9
-
121
-
-
68349107056
-
TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis
-
Rostad, K.; Hellwinkel, O.J.; Haukaas, S.A.; Halvorsen, O.J.; Oyan, A.M.; Haese, A.; Budaus, L.; Albrecht, H.; Akslen, L.A.; Schlomm, T., et al. TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis. APMIS 2009, 117, 575-582.
-
(2009)
APMIS
, vol.117
, pp. 575-582
-
-
Rostad, K.1
Hellwinkel, O.J.2
Haukaas, S.A.3
Halvorsen, O.J.4
Oyan, A.M.5
Haese, A.6
Budaus, L.7
Albrecht, H.8
Akslen, L.A.9
Schlomm, T.10
-
122
-
-
34248510706
-
TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort
-
Demichelis, F.; Fall, K.; Perner, S.; Andren, O.; Schmidt, F.; Setlur, S.R.; Hoshida, Y.; Mosquera, J.M.; Pawitan, Y.; Lee, C., et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 2007, 26, 4596-4599.
-
(2007)
Oncogene
, vol.26
, pp. 4596-4599
-
-
Demichelis, F.1
Fall, K.2
Perner, S.3
Andren, O.4
Schmidt, F.5
Setlur, S.R.6
Hoshida, Y.7
Mosquera, J.M.8
Pawitan, Y.9
Lee, C.10
-
123
-
-
83255192141
-
Developing therapeutic microRNAs for cancer
-
Bader, A.G.; Brown, D.; Stoudemire, J.; Lammers, P. Developing therapeutic microRNAs for cancer. Gene Ther. 2011, 18, 1121-1126.
-
(2011)
Gene Ther
, vol.18
, pp. 1121-1126
-
-
Bader, A.G.1
Brown, D.2
Stoudemire, J.3
Lammers, P.4
-
124
-
-
70350536585
-
Distinct microRNA alterations characterize high- and low-grade bladder cancer
-
Catto, J.W.; Miah, S.; Owen, H.C.; Bryant, H.; Myers, K.; Dudziec, E.; Larre, S.; Milo, M.; Rehman, I.; Rosario, D.J., et al. Distinct microRNA alterations characterize high- and low-grade bladder cancer. Cancer Res. 2009, 69, 8472-8481.
-
(2009)
Cancer Res
, vol.69
, pp. 8472-8481
-
-
Catto, J.W.1
Miah, S.2
Owen, H.C.3
Bryant, H.4
Myers, K.5
Dudziec, E.6
Larre, S.7
Milo, M.8
Rehman, I.9
Rosario, D.J.10
-
125
-
-
58249088751
-
MicroRNAs: Target recognition and regulatory functions
-
Bartel, D.P. MicroRNAs: Target recognition and regulatory functions. Cell 2009, 136, 215-233.
-
(2009)
Cell
, vol.136
, pp. 215-233
-
-
Bartel, D.P.1
-
127
-
-
39749110083
-
Small non-coding RNAs in animal development
-
Stefani, G.; Slack, F.J. Small non-coding RNAs in animal development. Nat. Rev. Mol. Cell. Biol. 2008, 9, 219-230.
-
(2008)
Nat. Rev. Mol. Cell. Biol
, vol.9
, pp. 219-230
-
-
Stefani, G.1
Slack, F.J.2
-
128
-
-
58849163959
-
MicroRNAs: Key regulators of stem cells
-
Gangaraju, V.K.; Lin, H. MicroRNAs: Key regulators of stem cells. Nat. Rev. Mol. Cell. Biol. 2009, 10, 116-125.
-
(2009)
Nat. Rev. Mol. Cell. Biol
, vol.10
, pp. 116-125
-
-
Gangaraju, V.K.1
Lin, H.2
-
129
-
-
70349320158
-
Causes and consequences of microRNA dysregulation in cancer
-
Croce, C.M. Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet. 2009, 10, 704-714.
-
(2009)
Nat. Rev. Genet
, vol.10
, pp. 704-714
-
-
Croce, C.M.1
-
130
-
-
84872195013
-
microRNA biomarkers in body fluids of prostate cancer patients
-
Kuner, R.; Brase, J.C.; Sultmann, H.; Wuttig, D. microRNA biomarkers in body fluids of prostate cancer patients. Methods 2013, 59, 132-137.
-
(2013)
Methods
, vol.59
, pp. 132-137
-
-
Kuner, R.1
Brase, J.C.2
Sultmann, H.3
Wuttig, D.4
-
131
-
-
20444460289
-
MicroRNA expression profiles classify human cancers
-
Lu, J.; Getz, G.; Miska, E.A.; Alvarez-Saavedra, E.; Lamb, J.; Peck, D.; Sweet-Cordero, A.; Ebert, B.L.; Mak, R.H.; Ferrando, A.A., et al. MicroRNA expression profiles classify human cancers. Nature 2005, 435, 834-838.
-
(2005)
Nature
, vol.435
, pp. 834-838
-
-
Lu, J.1
Getz, G.2
Miska, E.A.3
Alvarez-Saavedra, E.4
Lamb, J.5
Peck, D.6
Sweet-Cordero, A.7
Ebert, B.L.8
Mak, R.H.9
Ferrando, A.A.10
-
132
-
-
84869220331
-
MicroRNAs in prostate cancer: From biomarkers to molecularly-based therapeutics
-
Gordanpour, A.; Nam, R.K.; Sugar, L.; Seth, A. MicroRNAs in prostate cancer: From biomarkers to molecularly-based therapeutics. Prostate Cancer Prostatic Dis. 2012, 15, 314-319.
-
(2012)
Prostate Cancer Prostatic Dis
, vol.15
, pp. 314-319
-
-
Gordanpour, A.1
Nam, R.K.2
Sugar, L.3
Seth, A.4
-
133
-
-
78149484489
-
The microRNA spectrum in 12 body fluids
-
Weber, J.A.; Baxter, D.H.; Zhang, S.; Huang, D.Y.; Huang, K.H.; Lee, M.J.; Galas, D.J.; Wang, K. The microRNA spectrum in 12 body fluids. Clin. Chem. 2010, 56, 1733-1741.
-
(2010)
Clin. Chem
, vol.56
, pp. 1733-1741
-
-
Weber, J.A.1
Baxter, D.H.2
Zhang, S.3
Huang, D.Y.4
Huang, K.H.5
Lee, M.J.6
Galas, D.J.7
Wang, K.8
-
134
-
-
48749122914
-
Circulating microRNAs as stable blood-based markers for cancer detection
-
Mitchell, P.S.; Parkin, R.K.; Kroh, E.M.; Fritz, B.R.; Wyman, S.K.; Pogosova-Agadjanyan, E.L.; Peterson, A.; Noteboom, J.; O'Briant, K.C.; Allen, A., et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. USA 2008, 105, 10513-10518.
-
(2008)
Proc. Natl. Acad. Sci. USA
, vol.105
, pp. 10513-10518
-
-
Mitchell, P.S.1
Parkin, R.K.2
Kroh, E.M.3
Fritz, B.R.4
Wyman, S.K.5
Pogosova-Agadjanyan, E.L.6
Peterson, A.7
Noteboom, J.8
O'Briant, K.C.9
Allen, A.10
-
135
-
-
78649837502
-
Circulating miRNAs are correlated with tumor progression in prostate cancer
-
Brase, J.C.; Johannes, M.; Schlomm, T.; Falth, M.; Haese, A.; Steuber, T.; Beissbarth, T.; Kuner, R.; Sultmann, H. Circulating miRNAs are correlated with tumor progression in prostate cancer. Int. J. Cancer 2011, 128, 608-616.
-
(2011)
Int. J. Cancer
, vol.128
, pp. 608-616
-
-
Brase, J.C.1
Johannes, M.2
Schlomm, T.3
Falth, M.4
Haese, A.5
Steuber, T.6
Beissbarth, T.7
Kuner, R.8
Sultmann, H.9
-
136
-
-
79951704641
-
MiR-96 and miR-183 detection in urine serve as potential tumor markers of urothelial carcinoma: Correlation with stage and grade, and comparison with urinary cytology
-
Yamada, Y.; Enokida, H.; Kojima, S.; Kawakami, K.; Chiyomaru, T.; Tatarano, S.; Yoshino, H.; Kawahara, K.; Nishiyama, K.; Seki, N., et al. MiR-96 and miR-183 detection in urine serve as potential tumor markers of urothelial carcinoma: Correlation with stage and grade, and comparison with urinary cytology. Cancer Sci. 2011, 102, 522-529.
-
(2011)
Cancer Sci
, vol.102
, pp. 522-529
-
-
Yamada, Y.1
Enokida, H.2
Kojima, S.3
Kawakami, K.4
Chiyomaru, T.5
Tatarano, S.6
Yoshino, H.7
Kawahara, K.8
Nishiyama, K.9
Seki, N.10
-
137
-
-
84856812332
-
Changes in circulating microRNA levels associated with prostate cancer
-
Bryant, R.J.; Pawlowski, T.; Catto, J.W.; Marsden, G.; Vessella, R.L.; Rhees, B.; Kuslich, C.; Visakorpi, T.; Hamdy, F.C. Changes in circulating microRNA levels associated with prostate cancer. Br. J. Cancer 2012, 106, 768-774.
-
(2012)
Br. J. Cancer
, vol.106
, pp. 768-774
-
-
Bryant, R.J.1
Pawlowski, T.2
Catto, J.W.3
Marsden, G.4
Vessella, R.L.5
Rhees, B.6
Kuslich, C.7
Visakorpi, T.8
Hamdy, F.C.9
-
138
-
-
84879384665
-
Circulating MicroRNAs as biomarkers of prostate cancer: The state of play
-
539680:1-539680:10
-
Sapre, N.; Selth, L.A. Circulating MicroRNAs as biomarkers of prostate cancer: The state of play. Prostate Cancer 2013, 2013, 539680:1-539680:10.
-
(2013)
Prostate Cancer
-
-
Sapre, N.1
Selth, L.A.2
-
139
-
-
24744440117
-
Non-coding RNAs: New players in eukaryotic biology
-
Costa, F.F. Non-coding RNAs: New players in eukaryotic biology. Gene 2005, 357, 83-94.
-
(2005)
Gene
, vol.357
, pp. 83-94
-
-
Costa, F.F.1
-
141
-
-
40449110935
-
The enigmatic world of mRNA-like ncRNAs: Their role in human evolution and in human diseases
-
Szell, M.; Bata-Csorgo, Z.; Kemeny, L. The enigmatic world of mRNA-like ncRNAs: Their role in human evolution and in human diseases. Semin. Cancer Biol. 2008, 18, 141-148.
-
(2008)
Semin. Cancer Biol
, vol.18
, pp. 141-148
-
-
Szell, M.1
Bata-Csorgo, Z.2
Kemeny, L.3
-
142
-
-
77954098792
-
Controlling transcription with noncoding RNAs in mammalian cells
-
Turner, A.M.; Morris, K.V. Controlling transcription with noncoding RNAs in mammalian cells. Biotechniques 2010, 48, ix-xvi.
-
(2010)
Biotechniques
, vol.48
-
-
Turner, A.M.1
Morris, K.V.2
-
143
-
-
77956419405
-
The cancer cell secretome: A good source for discovering biomarkers?
-
Pavlou, M.P.; Diamandis, E.P. The cancer cell secretome: A good source for discovering biomarkers? J. Proteomics 2010, 73, 1896-1906.
-
(2010)
J. Proteomics
, vol.73
, pp. 1896-1906
-
-
Pavlou, M.P.1
Diamandis, E.P.2
-
144
-
-
77957755656
-
Secretome proteomics for discovery of cancer biomarkers
-
Makridakis, M.; Vlahou, A. Secretome proteomics for discovery of cancer biomarkers. J. Proteomics 2010, 73, 2291-2305.
-
(2010)
J. Proteomics
, vol.73
, pp. 2291-2305
-
-
Makridakis, M.1
Vlahou, A.2
-
145
-
-
73649116726
-
Identification of serum biomarkers for colorectal cancer metastasis using a differential secretome approach
-
Xue, H.; Lu, B.; Zhang, J.; Wu, M.; Huang, Q.; Wu, Q.; Sheng, H.; Wu, D.; Hu, J.; Lai, M. Identification of serum biomarkers for colorectal cancer metastasis using a differential secretome approach. J. Proteome Res. 2009, 9, 545-555.
-
(2009)
J. Proteome Res
, vol.9
, pp. 545-555
-
-
Xue, H.1
Lu, B.2
Zhang, J.3
Wu, M.4
Huang, Q.5
Wu, Q.6
Sheng, H.7
Wu, D.8
Hu, J.9
Lai, M.10
-
146
-
-
67651206765
-
Urinary PSA: A potential useful marker when serum PSA is between 2.5 ng/mL and 10 ng/mL
-
Bolduc, S.; Lacombe, L.; Naud, A.; Gregoire, M.; Fradet, Y.; Tremblay, R.R. Urinary PSA: A potential useful marker when serum PSA is between 2.5 ng/mL and 10 ng/mL. Can. Urol. Assoc. J. 2007, 1, 377-381.
-
(2007)
Can. Urol. Assoc. J
, vol.1
, pp. 377-381
-
-
Bolduc, S.1
Lacombe, L.2
Naud, A.3
Gregoire, M.4
Fradet, Y.5
Tremblay, R.R.6
-
147
-
-
0028157648
-
Urinary prostate specific antigen levels after radical prostatectomy
-
Takayama, T.K.; Vessella, R.L.; Brawer, M.K.; True, L.D.; Noteboom, J.; Lange, P.H. Urinary prostate specific antigen levels after radical prostatectomy. J. Urol. 1994, 151, 82-87.
-
(1994)
J. Urol
, vol.151
, pp. 82-87
-
-
Takayama, T.K.1
Vessella, R.L.2
Brawer, M.K.3
True, L.D.4
Noteboom, J.5
Lange, P.H.6
-
148
-
-
0026569058
-
Urinary prostate specific antigen levels: Role in monitoring the response of prostate cancer to therapy
-
DeVere White, R.W.; Meyers, F.J.; Soares, S.E.; Miller, D.G.; Soriano, T.F. Urinary prostate specific antigen levels: Role in monitoring the response of prostate cancer to therapy. J. Urol. 1992, 147, 947-951.
-
(1992)
J. Urol
, vol.147
, pp. 947-951
-
-
DeVere, W.R.W.1
Meyers, F.J.2
Soares, S.E.3
Miller, D.G.4
Soriano, T.F.5
-
149
-
-
0030721663
-
Molecular forms of prostate-specific antigen and human kallikrein 2 (hK2) in urine are not clinically useful for early detection and staging of prostate cancer
-
Pannek, J.; Rittenhouse, H.G.; Evans, C.L.; Finlay, J.A.; Bruzek, D.J.; Cox, J.L.; Chan, D.W.; Subong, E.N.; Partin, A.W. Molecular forms of prostate-specific antigen and human kallikrein 2 (hK2) in urine are not clinically useful for early detection and staging of prostate cancer. Urology 1997, 50, 715-721.
-
(1997)
Urology
, vol.50
, pp. 715-721
-
-
Pannek, J.1
Rittenhouse, H.G.2
Evans, C.L.3
Finlay, J.A.4
Bruzek, D.J.5
Cox, J.L.6
Chan, D.W.7
Subong, E.N.8
Partin, A.W.9
-
150
-
-
0031974108
-
Influence of digital rectal massage on urinary prostate-specific antigen: Interest for the detection of local recurrence after radical prostatectomy
-
Malavaud, B.; Salama, G.; Miedouge, M.; Vincent, C.; Rischmann, P.; Sarramon, J.P.; Serre, G. Influence of digital rectal massage on urinary prostate-specific antigen: Interest for the detection of local recurrence after radical prostatectomy. Prostate 1998, 34, 23-28.
-
(1998)
Prostate
, vol.34
, pp. 23-28
-
-
Malavaud, B.1
Salama, G.2
Miedouge, M.3
Vincent, C.4
Rischmann, P.5
Sarramon, J.P.6
Serre, G.7
-
151
-
-
57249095672
-
Annexin A3 in urine: A highly specific noninvasive marker for prostate cancer early detection
-
Schostak, M.; Schwall, G.P.; Poznanovic, S.; Groebe, K.; Muller, M.; Messinger, D.; Miller, K.; Krause, H.; Pelzer, A.; Horninger, W., et al. Annexin A3 in urine: A highly specific noninvasive marker for prostate cancer early detection. J. Urol. 2009, 181, 343-353.
-
(2009)
J. Urol
, vol.181
, pp. 343-353
-
-
Schostak, M.1
Schwall, G.P.2
Poznanovic, S.3
Groebe, K.4
Muller, M.5
Messinger, D.6
Miller, K.7
Krause, H.8
Pelzer, A.9
Horninger, W.10
-
152
-
-
53849144620
-
Strategies for discovering novel cancer biomarkers through utilization of emerging technologies
-
Kulasingam, V.; Diamandis, E.P. Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat. Clin. Pract. Oncol. 2008, 5, 588-599.
-
(2008)
Nat. Clin. Pract. Oncol
, vol.5
, pp. 588-599
-
-
Kulasingam, V.1
Diamandis, E.P.2
-
153
-
-
55049108997
-
Urine in clinical proteomics
-
Decramer, S.; Gonzalez de Peredo, A.; Breuil, B.; Mischak, H.; Monsarrat, B.; Bascands, J.L.; Schanstra, J.P. Urine in clinical proteomics. Mol. Cell Proteomics 2008, 7, 1850-1862.
-
(2008)
Mol. Cell Proteomics
, vol.7
, pp. 1850-1862
-
-
Decramer, S.1
de Peredo, G.A.2
Breuil, B.3
Mischak, H.4
Monsarrat, B.5
Bascands, J.L.6
Schanstra, J.P.7
-
154
-
-
10644231668
-
Proteomic analysis of voided urine after prostatic massage from patients with prostate cancer
-
Rehman, I.; Azzouzi, A.R.; Catto, J.W.; Allen, S.; Cross, S.S.; Feeley, K.; Meuth, M.; Hamdy, F.C. Proteomic analysis of voided urine after prostatic massage from patients with prostate cancer: A pilot study. Urology 2004, 64, 1238-1243.
-
(2004)
A Pilot Study. Urology
, vol.64
, pp. 1238-1243
-
-
Rehman, I.1
Azzouzi, A.R.2
Catto, J.W.3
Allen, S.4
Cross, S.S.5
Feeley, K.6
Meuth, M.7
Hamdy, F.C.8
-
155
-
-
23144461504
-
Pilot study of capillary electrophoresis coupled to mass spectrometry as a tool to define potential prostate cancer biomarkers in urine
-
Theodorescu, D.; Fliser, D.; Wittke, S.; Mischak, H.; Krebs, R.; Walden, M.; Ross, M.; Eltze, E.; Bettendorf, O.; Wulfing, C., et al. Pilot study of capillary electrophoresis coupled to mass spectrometry as a tool to define potential prostate cancer biomarkers in urine. Electrophoresis 2005, 26, 2797-2808.
-
(2005)
Electrophoresis
, vol.26
, pp. 2797-2808
-
-
Theodorescu, D.1
Fliser, D.2
Wittke, S.3
Mischak, H.4
Krebs, R.5
Walden, M.6
Ross, M.7
Eltze, E.8
Bettendorf, O.9
Wulfing, C.10
-
156
-
-
42449130178
-
Discovery and validation of urinary biomarkers for prostate cancer
-
Theodorescu, D.; Schiffer, E.; Bauer, H.W.; Douwes, F.; Eichhorn, F.; Polley, R.; Schmidt, T.; Schofer, W.; Zurbig, P.; Good, D.M., et al. Discovery and validation of urinary biomarkers for prostate cancer. Proteomics Clin. Appl. 2008, 2, 556-570.
-
(2008)
Proteomics Clin. Appl
, vol.2
, pp. 556-570
-
-
Theodorescu, D.1
Schiffer, E.2
Bauer, H.W.3
Douwes, F.4
Eichhorn, F.5
Polley, R.6
Schmidt, T.7
Schofer, W.8
Zurbig, P.9
Good, D.M.10
-
157
-
-
33846027431
-
Detection of pre-neoplastic and neoplastic prostate disease by MALDI profiling of urine
-
M'Koma, A.E.; Blum, D.L.; Norris, J.L.; Koyama, T.; Billheimer, D.; Motley, S.; Ghiassi, M.; Ferdowsi, N.; Bhowmick, I.; Chang, S.S., et al. Detection of pre-neoplastic and neoplastic prostate disease by MALDI profiling of urine. Biochem. Biophys. Res. Commun. 2007, 353, 829-834.
-
(2007)
Biochem. Biophys. Res. Commun
, vol.353
, pp. 829-834
-
-
M'Koma, A.E.1
Blum, D.L.2
Norris, J.L.3
Koyama, T.4
Billheimer, D.5
Motley, S.6
Ghiassi, M.7
Ferdowsi, N.8
Bhowmick, I.9
Chang, S.S.10
-
158
-
-
61449318282
-
Protein profiling of post-prostatic massage urine specimens by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry to discriminate between prostate cancer and benign lesions
-
Okamoto, A.; Yamamoto, H.; Imai, A.; Hatakeyama, S.; Iwabuchi, I.; Yoneyama, T.; Hashimoto, Y.; Koie, T.; Kamimura, N.; Mori, K., et al. Protein profiling of post-prostatic massage urine specimens by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry to discriminate between prostate cancer and benign lesions. Oncol. Rep. 2009, 21, 73-79.
-
(2009)
Oncol. Rep
, vol.21
, pp. 73-79
-
-
Okamoto, A.1
Yamamoto, H.2
Imai, A.3
Hatakeyama, S.4
Iwabuchi, I.5
Yoneyama, T.6
Hashimoto, Y.7
Koie, T.8
Kamimura, N.9
Mori, K.10
-
159
-
-
84861896039
-
Validation study of urinary metabolites as potential biomarkers for prostate cancer detection
-
Gamagedara, S.; Kaczmarek, A.T.; Jiang, Y.; Cheng, X.; Rupasinghe, M.; Ma, Y. Validation study of urinary metabolites as potential biomarkers for prostate cancer detection. Bioanalysis 2012, 4, 1175-1183.
-
(2012)
Bioanalysis
, vol.4
, pp. 1175-1183
-
-
Gamagedara, S.1
Kaczmarek, A.T.2
Jiang, Y.3
Cheng, X.4
Rupasinghe, M.5
Ma, Y.6
-
160
-
-
77955517340
-
Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumors
-
discussion 20-21
-
Jentzmik, F.; Stephan, C.; Miller, K.; Schrader, M.; Erbersdobler, A.; Kristiansen, G.; Lein, M.; Jung, K. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumors. Eur. Urol. 2010, 58, 12-18; discussion 20-21.
-
(2010)
Eur. Urol
, vol.58
, pp. 12-18
-
-
Jentzmik, F.1
Stephan, C.2
Miller, K.3
Schrader, M.4
Erbersdobler, A.5
Kristiansen, G.6
Lein, M.7
Jung, K.8
-
161
-
-
17044367510
-
Use of multiple biomarkers for a molecular diagnosis of prostate cancer
-
Landers, K.A.; Burger, M.J.; Tebay, M.A.; Purdie, D.M.; Scells, B.; Samaratunga, H.; Lavin, M.F.; Gardiner, R.A. Use of multiple biomarkers for a molecular diagnosis of prostate cancer. Int. J. Cancer 2005, 114, 950-956.
-
(2005)
Int. J. Cancer
, vol.114
, pp. 950-956
-
-
Landers, K.A.1
Burger, M.J.2
Tebay, M.A.3
Purdie, D.M.4
Scells, B.5
Samaratunga, H.6
Lavin, M.F.7
Gardiner, R.A.8
-
162
-
-
33749069496
-
Quantitative multi-gene expression profiling of primary prostate cancer
-
Schmidt, U.; Fuessel, S.; Koch, R.; Baretton, G.B.; Lohse, A.; Tomasetti, S.; Unversucht, S.; Froehner, M.; Wirth, M.P.; Meye, A. Quantitative multi-gene expression profiling of primary prostate cancer. Prostate 2006, 66, 1521-1534.
-
(2006)
Prostate
, vol.66
, pp. 1521-1534
-
-
Schmidt, U.1
Fuessel, S.2
Koch, R.3
Baretton, G.B.4
Lohse, A.5
Tomasetti, S.6
Unversucht, S.7
Froehner, M.8
Wirth, M.P.9
Meye, A.10
-
163
-
-
2942658010
-
Combining biomarkers to detect disease with application to prostate cancer
-
Etzioni, R.; Kooperberg, C.; Pepe, M.; Smith, R.; Gann, P.H. Combining biomarkers to detect disease with application to prostate cancer. Biostatistics 2003, 4, 523-538.
-
(2003)
Biostatistics
, vol.4
, pp. 523-538
-
-
Etzioni, R.1
Kooperberg, C.2
Pepe, M.3
Smith, R.4
Gann, P.H.5
-
164
-
-
68149170832
-
Multicenter evaluation of an investigational prostate cancer methylation assay
-
Baden, J.; Green, G.; Painter, J.; Curtin, K.; Markiewicz, J.; Jones, J.; Astacio, T.; Canning, S.; Quijano, J.; Guinto, W., et al. Multicenter evaluation of an investigational prostate cancer methylation assay. J. Urol. 2009, 182, 1186-1193.
-
(2009)
J. Urol
, vol.182
, pp. 1186-1193
-
-
Baden, J.1
Green, G.2
Painter, J.3
Curtin, K.4
Markiewicz, J.5
Jones, J.6
Astacio, T.7
Canning, S.8
Quijano, J.9
Guinto, W.10
-
165
-
-
43449117779
-
Development of a multiplexed urine assay for prostate cancer diagnosis
-
Vener, T.; Derecho, C.; Baden, J.; Wang, H.; Rajpurohit, Y.; Skelton, J.; Mehrotra, J.; Varde, S.; Chowdary, D.; Stallings, W., et al. Development of a multiplexed urine assay for prostate cancer diagnosis. Clin. Chem. 2008, 54, 874-882.
-
(2008)
Clin. Chem
, vol.54
, pp. 874-882
-
-
Vener, T.1
Derecho, C.2
Baden, J.3
Wang, H.4
Rajpurohit, Y.5
Skelton, J.6
Mehrotra, J.7
Varde, S.8
Chowdary, D.9
Stallings, W.10
-
166
-
-
67650911920
-
DNA methylation biomarkers of prostate cancer: Confirmation of candidates and evidence urine is the most sensitive body fluid for non-invasive detection
-
Payne, S.R.; Serth, J.; Schostak, M.; Kamradt, J.; Strauss, A.; Thelen, P.; Model, F.; Day, J.K.; Liebenberg, V.; Morotti, A., et al. DNA methylation biomarkers of prostate cancer: Confirmation of candidates and evidence urine is the most sensitive body fluid for non-invasive detection. Prostate 2009, 69, 1257-1269.
-
(2009)
Prostate
, vol.69
, pp. 1257-1269
-
-
Payne, S.R.1
Serth, J.2
Schostak, M.3
Kamradt, J.4
Strauss, A.5
Thelen, P.6
Model, F.7
Day, J.K.8
Liebenberg, V.9
Morotti, A.10
-
167
-
-
67349271704
-
A duplex quantitative polymerase chain reaction assay based on quantification of alpha-methylacyl-CoA racemase transcripts and prostate cancer antigen 3 in urine sediments improved diagnostic accuracy for prostate cancer
-
discussion 2513-2514
-
Ouyang, B.; Bracken, B.; Burke, B.; Chung, E.; Liang, J.; Ho, S.M. A duplex quantitative polymerase chain reaction assay based on quantification of alpha-methylacyl-CoA racemase transcripts and prostate cancer antigen 3 in urine sediments improved diagnostic accuracy for prostate cancer. J. Urol. 2009, 181, 2508-2513; discussion 2513-2514.
-
(2009)
J. Urol
, vol.181
, pp. 2508-2513
-
-
Ouyang, B.1
Bracken, B.2
Burke, B.3
Chung, E.4
Liang, J.5
Ho, S.M.6
-
168
-
-
84879461124
-
Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer
-
doi:10.1016/j.urolonc.2011.04.001
-
Salami, S.S.; Schmidt, F.; Laxman, B.; Regan, M.M.; Rickman, D.S.; Scherr, D.; Bueti, G.; Siddiqui, J.; Tomlins, S.A.; Wei, J.T., et al. Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. Urol. Oncol. 2011, doi:10.1016/j.urolonc.2011.04.001.
-
(2011)
Urol. Oncol
-
-
Salami, S.S.1
Schmidt, F.2
Laxman, B.3
Regan, M.M.4
Rickman, D.S.5
Scherr, D.6
Bueti, G.7
Siddiqui, J.8
Tomlins, S.A.9
Wei, J.T.10
-
169
-
-
76949097672
-
Urine markers in monitoring for prostate cancer
-
Jamaspishvili, T.; Kral, M.; Khomeriki, I.; Student, V.; Kolar, Z.; Bouchal, J. Urine markers in monitoring for prostate cancer. Prostate Cancer Prostatic Dis. 2011, 13, 12-19.
-
(2011)
Prostate Cancer Prostatic Dis
, vol.13
, pp. 12-19
-
-
Jamaspishvili, T.1
Kral, M.2
Khomeriki, I.3
Student, V.4
Kolar, Z.5
Bouchal, J.6
-
170
-
-
79551482646
-
A panel of TMPRSS2:ERG fusion transcript markers for urine-based prostate cancer detection with high specificity and sensitivity
-
Nguyen, P.N.; Violette, P.; Chan, S.; Tanguay, S.; Kassouf, W.; Aprikian, A.; Chen, J.Z. A panel of TMPRSS2:ERG fusion transcript markers for urine-based prostate cancer detection with high specificity and sensitivity. Eur. Urol. 2011, 59, 407-414.
-
(2011)
Eur. Urol
, vol.59
, pp. 407-414
-
-
Nguyen, P.N.1
Violette, P.2
Chan, S.3
Tanguay, S.4
Kassouf, W.5
Aprikian, A.6
Chen, J.Z.7
-
171
-
-
79961222799
-
Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA
-
Tomlins, S.A.; Aubin, S.M.; Siddiqui, J.; Lonigro, R.J.; Sefton-Miller, L.; Miick, S.; Williamsen, S.; Hodge, P.; Meinke, J.; Blase, A., et al. Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci. Transl. Med. 2011, 3, 94ra72.
-
(2011)
Sci. Transl. Med
, vol.3
-
-
Tomlins, S.A.1
Aubin, S.M.2
Siddiqui, J.3
Lonigro, R.J.4
Sefton-Miller, L.5
Miick, S.6
Williamsen, S.7
Hodge, P.8
Meinke, J.9
Blase, A.10
-
172
-
-
79953700273
-
A multiplex model of combining gene-based, protein-based, and metabolite-based with positive and negative markers in urine for the early diagnosis of prostate cancer
-
Cao, D.L.; Ye, D.W.; Zhang, H.L.; Zhu, Y.; Wang, Y.X.; Yao, X.D. A multiplex model of combining gene-based, protein-based, and metabolite-based with positive and negative markers in urine for the early diagnosis of prostate cancer. Prostate 2011, 71, 700-710.
-
(2011)
Prostate
, vol.71
, pp. 700-710
-
-
Cao, D.L.1
Ye, D.W.2
Zhang, H.L.3
Zhu, Y.4
Wang, Y.X.5
Yao, X.D.6
-
173
-
-
78049465549
-
Use of a combination of biomarkers in serum and urine to improve detection of prostate cancer
-
Prior, C.; Guillen-Grima, F.; Robles, J.E.; Rosell, D.; Fernandez-Montero, J.M.; Agirre, X.; Catena, R.; Calvo, A. Use of a combination of biomarkers in serum and urine to improve detection of prostate cancer. World J. Urol. 2010, 28, 681-686.
-
(2010)
World J. Urol
, vol.2
, pp. 681-686
-
-
Prior, C.1
Guillen-Grima, F.2
Robles, J.E.3
Rosell, D.4
Fernandez-Montero, J.M.5
Agirre, X.6
Catena, R.7
Calvo, A.8
-
174
-
-
0036676445
-
Exosomes: Composition, biogenesis and function
-
Thery, C.; Zitvogel, L.; Amigorena, S. Exosomes: Composition, biogenesis and function. Nat. Rev. Immunol. 2002, 2, 569-579.
-
(2002)
Nat. Rev. Immunol
, vol.2
, pp. 569-579
-
-
Thery, C.1
Zitvogel, L.2
Amigorena, S.3
-
175
-
-
55749112807
-
Proteomic profiling of exosomes: Current perspectives
-
Simpson, R.J.; Jensen, S.S.; Lim, J.W. Proteomic profiling of exosomes: Current perspectives. Proteomics 2008, 8, 4083-4099.
-
(2008)
Proteomics
, vol.8
, pp. 4083-4099
-
-
Simpson, R.J.1
Jensen, S.S.2
Lim, J.W.3
-
176
-
-
76949101800
-
Astrocytes and Glioblastoma cells release exosomes carrying mtDNA
-
Guescini, M.; Genedani, S.; Stocchi, V.; Agnati, L.F. Astrocytes and Glioblastoma cells release exosomes carrying mtDNA. J. Neural Transm. 2010, 117, 1-4.
-
(2010)
J. Neural Transm
, vol.117
, pp. 1-4
-
-
Guescini, M.1
Genedani, S.2
Stocchi, V.3
Agnati, L.F.4
-
177
-
-
79958048581
-
Body fluid derived exosomes as a novel template for clinical diagnostics
-
Keller, S.; Ridinger, J.; Rupp, A.K.; Janssen, J.W.; Altevogt, P. Body fluid derived exosomes as a novel template for clinical diagnostics. J. Transl. Med. 2011, 9, 86.
-
(2011)
J. Transl. Med
, vol.9
, pp. 86
-
-
Keller, S.1
Ridinger, J.2
Rupp, A.K.3
Janssen, J.W.4
Altevogt, P.5
-
178
-
-
33646161950
-
Collection, storage, preservation, and normalization of human urinary exosomes for biomarker discovery
-
Zhou, H.; Yuen, P.S.; Pisitkun, T.; Gonzales, P.A.; Yasuda, H.; Dear, J.W.; Gross, P.; Knepper, M.A.; Star, R.A. Collection, storage, preservation, and normalization of human urinary exosomes for biomarker discovery. Kidney Int. 2006, 69, 1471-1476.
-
(2006)
Kidney Int
, vol.69
, pp. 1471-1476
-
-
Zhou, H.1
Yuen, P.S.2
Pisitkun, T.3
Gonzales, P.A.4
Yasuda, H.5
Dear, J.W.6
Gross, P.7
Knepper, M.A.8
Star, R.A.9
-
179
-
-
67349142591
-
Prostate cancer-derived urine exosomes: A novel approach to biomarkers for prostate cancer
-
Nilsson, J.; Skog, J.; Nordstrand, A.; Baranov, V.; Mincheva-Nilsson, L.; Breakefield, X.O.; Widmark, A. Prostate cancer-derived urine exosomes: A novel approach to biomarkers for prostate cancer. Br. J. Cancer 2009, 100, 1603-1607.
-
(2009)
Br. J. Cancer
, vol.100
, pp. 1603-1607
-
-
Nilsson, J.1
Skog, J.2
Nordstrand, A.3
Baranov, V.4
Mincheva-Nilsson, L.5
Breakefield, X.O.6
Widmark, A.7
-
180
-
-
84876186916
-
Exosomal miRNAs as biomarkers for prostate cancer
-
Hessvik, N.P.; Sandvig, K.; Llorente, A. Exosomal miRNAs as biomarkers for prostate cancer. Front Genet 2013, 4, 36.
-
(2013)
Front Genet
, vol.4
, pp. 36
-
-
Hessvik, N.P.1
Sandvig, K.2
Llorente, A.3
-
181
-
-
33846785860
-
Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer
-
Laxman, B.; Tomlins, S.A.; Mehra, R.; Morris, D.S.; Wang, L.; Helgeson, B.E.; Shah, R.B.; Rubin, M.A.; Wei, J.T.; Chinnaiyan, A.M. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. Neoplasia 2006, 8, 885-888.
-
(2006)
Neoplasia
, vol.8
, pp. 885-888
-
-
Laxman, B.1
Tomlins, S.A.2
Mehra, R.3
Morris, D.S.4
Wang, L.5
Helgeson, B.E.6
Shah, R.B.7
Rubin, M.A.8
Wei, J.T.9
Chinnaiyan, A.M.10
-
182
-
-
65949096925
-
Biomarkers for prostate cancer
-
Makarov, D.V.; Loeb, S.; Getzenberg, R.H.; Partin, A.W. Biomarkers for prostate cancer. Annu. Rev. Med. 2009, 60, 139-151.
-
(2009)
Annu. Rev. Med
, vol.60
, pp. 139-151
-
-
Makarov, D.V.1
Loeb, S.2
Getzenberg, R.H.3
Partin, A.W.4
-
183
-
-
77049108648
-
Urine biomarkers in prostate cancer
-
Ploussard, G.; de la Taille, A. Urine biomarkers in prostate cancer. Nat. Rev. Urol. 2010, 7, 101-109.
-
(2010)
Nat. Rev. Urol
, vol.7
, pp. 101-109
-
-
Ploussard, G.1
de la Taille, A.2
|